var title_f43_12_44224="Generation of the P wave";
var content_f43_12_44224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Generation of the P wave",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With normal sinus rhythm, the atrial depolarization vector is directed from the right atrium to the left atrium and downward towards the AV junction (arrow). As a result, the P wave will normally be upright in lead II and negative in lead aVR.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44224=[""].join("\n");
var outline_f43_12_44224=null;
var title_f43_12_44225="Orientation adjuster";
var content_f43_12_44225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Orientation adjuster",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture showing the orientation adjuster (insert showing its effect on the trucut needle).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44225=[""].join("\n");
var outline_f43_12_44225=null;
var title_f43_12_44226="Parasternal short axis view tetralogy of Fallot";
var content_f43_12_44226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1042px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PEDS/72460/Parastern_short_axis_view.mp4?title=Parasternal+short+axis+view+tetralogy+of+Fallot\" style=\"width:432px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Parasternal short axis view in tetralogy of Fallot (TOF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This still frame from the accompanying echocardiographic video clip of the parasternal short axis view of a patient with tetralogy of Fallot (TOF) demonstrates the dynamic obstruction in the right ventricular outflow tract (RVOT) and the hypoplastic pulmonary annulus. The main and branch pulmonary arteries are also imaged.",
"    <div class=\"footnotes\">",
"     Ao: aorta; RPA: right pulmonary artery; LPA: left pulmonary artery; MPA: main pulmonary artery; LA: left atrium; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44226=[""].join("\n");
var outline_f43_12_44226=null;
var title_f43_12_44227="Triptorelin: Patient drug information";
var content_f43_12_44227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Triptorelin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/11/9398?source=see_link\">",
"     see \"Triptorelin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trelstar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Decapeptyl&reg;;",
"     </li>",
"     <li>",
"      Trelstar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703092",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to triptorelin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696728",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Disease signs may get worse before getting better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More bone pain, blood in urine, and trouble passing urine. Most often gets better 1 to 2 weeks after care has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698960",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More bone pain after 2 to 4 weeks of care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11131 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44227=[""].join("\n");
var outline_f43_12_44227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231908\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231909\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016169\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016168\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016173\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016174\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016176\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016171\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016178\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/11/9398?source=related_link\">",
"      Triptorelin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_12_44228="Stroop test";
var content_f43_12_44228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F72016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F72016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Stroop test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Stroop Color&nbsp;Word&nbsp;Interference Test examines the ability to direct attention. After first confirming that the subject can appropriately read the color names and name the colors (top two panels), he/she is asked to name the color of the ink that the&nbsp;word is printed in (third panel). As an example, the patient should say for the first row of the third panel \"Blue, Green, Blue, Blue, Red, Green.\" The test is scored based on speed and accuracy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44228=[""].join("\n");
var outline_f43_12_44228=null;
var title_f43_12_44229="Doxercalciferol: Drug information";
var content_f43_12_44229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Doxercalciferol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/9/20628?source=see_link\">",
"    see \"Doxercalciferol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F163084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hectorol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F163085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hectorol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F163101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin D Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F163088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Secondary hyperparathyroidism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis patients: Dose should be titrated to lower iPTH to 150-300 pg/mL; dose is adjusted at 8-week intervals (maximum dose: 20 mcg 3 times/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: iPTH &gt;400 pg/mL: 10 mcg 3 times/week at dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose titration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level decreased by 50% and &gt;300 pg/mL: Dose can be increased to 12.5 mcg 3 times/week for 8 more weeks; this titration process can continue at 8-week intervals; each increase should be by 2.5 mcg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level 150-300 pg/mL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level &lt;100 pg/mL: Suspend doxercalciferol for 1 week; resume at a reduced dose; decrease each dose (not weekly dose) by at least 2.5 mcg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Predialysis patients: Dose should be titrated to lower iPTH to 35-70 pg/mL with stage 3 disease or to 70-110 pg/mL with stage 4 disease: Dose may be adjusted at 2-week intervals (maximum dose: 3.5 mcg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: 1 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose titration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level &gt;70 pg/mL with stage 3 disease or &gt;110 pg/mL with stage 4 disease: Increase dose by 0.5 mcg every 2 weeks as necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level 35-70 pg/mL with stage 3 disease or 70-110 pg/mL with stage 4 disease: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level is &lt;35 pg/mL with stage 3 disease or &lt;70 pg/mL with stage 4 disease: Suspend doxercalciferol for 1 week, then resume at a reduced dose (at least 0.5 mcg lower)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis patients: Dose should be titrated to lower iPTH to 150-300 pg/mL; dose is adjusted at 8-week intervals (maximum dose: 18 mcg/week)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: iPTH level &gt;400 pg/mL: 4 mcg 3 times/week after dialysis, administered as a bolus dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose titration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level decreased by &lt;50% and &gt;300 pg/mL: Dose can be increased by 1-2 mcg at 8-week intervals, as necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level decreased by &gt;50% and &gt;300 pg/mL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level 150-300 pg/mL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     iPTH level &lt;100 pg/mL: Suspend doxercalciferol for 1 week; resume at a reduced dose (at least 1 mcg lower)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Hypercalcemia, hyperphosphatemia, or serum calcium times phosphorus product &gt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"     : Decrease or suspend dose and/or adjust dose of phosphate binders; if dose is suspended, resume at a reduced dose (at least 1 mcg lower)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F163089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F163090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F163091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; no guidelines for dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F163067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hectorol&reg;: 0.5 mcg, 1 mcg, 2.5 mcg [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hectorol&reg;: 2 mcg/mL (1 mL, 2 mL) [contains edetate disodium, ethanol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F163052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F163069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of secondary hyperparathyroidism in patients with chronic kidney disease",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F163099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     As reported in dialysis patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (28%), malaise (28%), dizziness (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Sleep disorder (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia (I.V. ~1%), hyperphosphatemia (I.V. 2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (5%), dyspepsia (5%), weight gain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Abscess (3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F163072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of hypercalcemia or evidence of vitamin D toxicity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F163056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Excessive vitamin D: Excessive vitamin D administration may lead to over suppression of PTH, progressive or acute hypercalcemia, hypercalciuria, hyperphosphatemia and adynamic bone disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: Progressive and/or acute hypercalcemia may increase risk of cardiac arrhythmias and seizures; chronic hypercalcemia may lead to generalized vascular and other soft-tissue calcification. Phosphate and vitamin D (and its derivatives) should be withheld during therapy to avoid hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperphosphatemia: Should be corrected before initiating therapy; exacerbates secondary hyperparathyroidism, diminishing the effect of doxercalciferol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients taking cardiac glycosides; digitalis toxicity is potentiated by hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Intended for I.V. use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Other forms of vitamin D should be discontinued when doxercalciferol is started.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F163061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically, mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant, oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May decrease the serum concentration of Vitamin D Analogs. More specifically, orlistat may impair absorption of Vitamin D Analogs. Management: Monitor clinical response (including serum calcium) to oral vitamin D analogs closely if used with orlistat.  If this combination must be used, consider giving the vitamin D analog at least 2 hrs before or after orlistat.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May enhance the adverse/toxic effect of other Vitamin D Analogs.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F163063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F163075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction in animals (usual and high dose) do not reveal teratogenic or fetotoxic effects.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F163094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F163076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk is unknown. Other vitamin D derivatives are excreted in breast milk; there is a potential for adverse effects. Therefore, the manufacturer recommends that breast-feeding be discontinued or doxercalciferol discontinued, depending upon importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F163077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on serum levels, dietary phosphorus may be restricted and/or controlled with calcium-based phosphorus binders. The daily combined calcium intake (dietary and calcium based phosphate binder) should be 1.5-2 g. Additional vitamin D supplements and magnesium-containing antacids should be avoided. Capsules contain coconut oil.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F163074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Hectorol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5 mcg (50): $558.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mcg (50): $1116.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mcg (50): $1293.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hectorol Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mcg/mL (1 mL): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mcg/2 mL (2 mL): $15.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F163065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum calcium and phosphorus: Frequency of measurement may be dependent upon the presence and magnitude of abnormalities, the rate of progression of CKD, and the use of treatments for CKD-mineral and bone disorders (KDIGO, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 3: Every 6-12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 4: Every 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CKD stage 5 and 5D: Every 1-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Periodic 24-hour urinary calcium and phosphorus; magnesium; alkaline phosphatase every 12 months or more frequently in the presence of elevated PTH; creatinine, BUN, albumin; intact parathyroid hormone (iPTH) every 3-12 months depending on CKD severity",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F163068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corrected total serum calcium (K/DOQI, 2003): CKD stages 3 and 4: 8.4-10.2 mg/dL (2.1-2.6 mmol/L); CKD stage 5: 8.4-9.5 mg/dL (2.1-2.37 mmol/L); KDIGO guidelines recommend maintaining normal ranges for all stages of CKD (3-5D) (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphorus (K/DOQI, 2003): CKD stages 3 and 4: 2.7-4.6 mg/dL (0.87-1.48 mmol/L); CKD stage 5 (including those treated with dialysis): 3.5-5.5 mg/dL (1.13-1.78 mmol/L); KDIGO guidelines recommend maintaining normal ranges for CKD stages 3-5 and lowering elevated phosphorus levels toward the normal range for CKD stage 5D (KDIGO, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum calcium-phosphorus product (K/DOQI, 2003): CKD stage 3-5: &lt;55 mg",
"     <sup>",
"      2",
"     </sup>",
"     /dL",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PTH: Whole molecule, immunochemiluminometric assay (ICMA): 1.0-5.2 pmol/L; whole molecule, radioimmunoassay (RIA): 10.0-65.0 pg/mL; whole molecule, immunoradiometric, double antibody (IRMA): 1.0-6.0 pmol/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Target ranges by stage of chronic kidney disease (KDIGO, 2009): CKD stage 3-5: Optimal iPTH is unknown; maintain normal range (assay-dependent); CKD stage 5D: Maintain iPTH within 2-9 times the upper limit of normal for the assay used",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F163078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hectorol (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F163055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doxercalciferol is metabolized to the active form of vitamin D. The active form of vitamin D controls the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidneys, and in conjunction with PTH, the mobilization of calcium from the skeleton.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F163071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP27 to active metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Active metabolite: 32-37 hours; up to 96 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Eknoyan G, Levin A, and Levin NW, &ldquo;Bone Metabolism and Disease in Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2003, 42(4 Suppl 3):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 1. Evaluation of Calcium and Phosphorus Metabolism.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide1.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 3. Evaluation of Serum Phosphorus Levels.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide3.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 6. Serum Calcium and Calcium-Phosphorus Product.&rdquo; Available at  file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide6.htm",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44229/abstract-text/14520607/pubmed\" id=\"14520607\" target=\"_blank\">",
"        14520607",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8A. Active Vitamin D Therapy in Patients With Stages 3 and 4 CKD.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide8A.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, Guideline 8B. Vitamin D Therapy in Patients on Dialysis (CKD Stage 5).\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_bone/Guide8B.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Part 4. Definition and Classification of Stages of Chronic Kidney Disease.\" Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/p4_class.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group, \"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD),\"",
"      <i>",
"       Kidney Int Suppl",
"      </i>",
"      , 2009, 76(S113):1-130.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44229/abstract-text/19644521/pubmed\" id=\"19644521\" target=\"_blank\">",
"        19644521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8651 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-99A7E1262A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44229=[""].join("\n");
var outline_f43_12_44229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163084\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163085\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163101\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163088\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163089\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163090\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163091\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163052\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163069\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163099\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163072\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163056\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299232\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163061\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163063\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163075\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163094\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163076\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163077\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163074\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163065\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163068\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163078\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163055\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F163071\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8651\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8651|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/9/20628?source=related_link\">",
"      Doxercalciferol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_12_44230="Viral load testing for cytomegalovirus in solid organ transplant recipients";
var content_f43_12_44230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Viral load testing for cytomegalovirus in solid organ transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44230/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44230/contributors\">",
"     Angela M Caliendo, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44230/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44230/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/12/44230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) remains a major pathogen for solid organ transplant recipients, causing febrile syndromes, hepatitis, pneumonitis, retinitis, and colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/1\">",
"     1",
"    </a>",
"    ]. Because CMV produces lifelong latent infection, differentiation of latent infection from active disease in immunocompromised individuals presents a diagnostic challenge. The administration of antiviral agents for prophylaxis against the development of active CMV disease has been common in transplant programs. However, identifying the patients who are most likely to require treatment and initiating preemptive therapy is a strategy that has gained prominence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    .) Such an approach depends upon sensitive and specific testing modalities.",
"   </p>",
"   <p>",
"    Qualitative CMV polymerase chain reaction (PCR) assays are very sensitive, but since CMV DNA can be detected in patients without active disease, the clinical utility of these tests is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Several different approaches have been used in an effort to increase the clinical specificity of molecular tests for CMV, including detecting CMV DNA in plasma rather than whole blood or leukocytes, the use of quantitative assays, and detection of mRNA. Quantitative assays are now widely used. The different quantitative CMV DNA assays and their clinical utility will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR ASSAYS FOR THE QUANTIFICATION OF CMV DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of molecular assays have been developed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      COBAS",
"      <span class=\"nowrap\">",
"       AmpliPrep/COBAS",
"      </span>",
"      TaqMan CMV test &mdash; The COBAS",
"      <span class=\"nowrap\">",
"       AmpliPrep/COBAS",
"      </span>",
"      TaqMan CMV test (Roche Molecular Diagnostics, Pleasanton, CA) is a PCR-based assay that uses an international standard to quantitate the CMV load in plasma with a reported range between 150 and 10,000,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (or between 137 and 9,100,000",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/5\">",
"       5",
"      </a>",
"      ]. This test was approved by the US Food and Drug Administration in July 2012 for serial testing to evaluate changes in CMV load in solid organ transplant recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      COBAS Amplicor cytomegalovirus (CMV) Monitor test &mdash; The COBAS Amplicor cytomegalovirus (CMV) Monitor test (Roche Molecular Diagnostics, Pleasanton, CA), which is available as a Research Use Only product, is a polymerase chain reaction- (PCR) based assay that amplifies a 365 base pair region of the CMV polymerase gene. The manufacturer reports that the dynamic range of the assay is between 600 and 100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/7\">",
"       7",
"      </a>",
"      ]. One study has shown that the upper limit of the linear range is 50,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/8\">",
"       8",
"      </a>",
"      ]. The assay has been designed for use with plasma, leukocyte, and whole blood specimens. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Laboratory-developed PCR assays &mdash; There are a variety of analyte specific reagents available to assist laboratories in the development of assays. Most laboratory-developed assays use real-time PCR technologies, which have several advantages compared to standard PCR methods, including decreased risk of carryover contamination, broader linear range, and more rapid turnaround time. The performance, sensitivity, and linear range of laboratory-developed assays vary because of different specimen types, nucleic acid extraction methods, gene targets, primers, probes, detection methods, and quantitation standards. As a result, there may not be close agreement in viral load values among laboratories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Comparison of tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variability of viral load values was assessed in a multicenter study involving 33 laboratories in the United States, Europe, and Canada; this study showed that the variability of the viral load values for individual samples ranged from 2.0 to 4.3 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/9\">",
"     9",
"    </a>",
"    ]. For example, a CMV DNA value of 100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    in one laboratory may be reported as 100",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (3 log",
"    <sub>",
"     10",
"    </sub>",
"    difference) when using an assay developed by a different laboratory. In 2010, an international standard developed by the World Health Organization (WHO) and composed of a standardized amount of CMV became available from the National Institute of Biological Standards and Controls in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/10\">",
"     10",
"    </a>",
"    ]. The availability of this reference reagent is an important advance in CMV testing, since it allows for the standardization of viral load values among different laboratory-developed tests when results are expressed as international",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     (IU/mL).",
"    </span>",
"    This should facilitate clinical studies to determine the viral load values that correlate with the development of clinical disease.",
"   </p>",
"   <p>",
"    Multiple studies have evaluated the performance characteristics of the various assays available for quantitative viral load testing for CMV with the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/8,11-19\">",
"     8,11-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An international multicenter study compared the COBAS",
"      <span class=\"nowrap\">",
"       AmpliPrep/COBAS",
"      </span>",
"      TaqMan CMV test to laboratory-developed PCR assays at five transplant centers using a panel of samples prepared from CMV virus stock (at six dilutions ranging from 2.18 to 6.7 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      and the CMV standards developed by the WHO [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/19\">",
"       19",
"      </a>",
"      ]. The level of agreement was high for the COBAS",
"      <span class=\"nowrap\">",
"       AmpliPrep/COBAS",
"      </span>",
"      TaqMan CMV test across different laboratories as demonstrated by a smaller range of mean concentrations of CMV panel members by site and narrower confidence intervals of the combined data for each CMV panel member compared with laboratory-developed PCR assays.",
"     </li>",
"     <li>",
"      When compared side-by-side, results from the Amplicor PCR test and the pp65 antigenemia assay correlated well when used to diagnose active CMV disease, screen patients for use of preemptive therapy, or monitor response to therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. Of note, the values in the pp65 antigenemia assay will not agree with viral load values since the antigenemia assay measures viral antigen within neutrophils, whereas the viral load assays measure viral nucleic acid in plasma.",
"     </li>",
"     <li>",
"      A study evaluating the reproducibility of the Amplicor PCR test in three different laboratories found greater variation at lower copy number [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/8\">",
"       8",
"      </a>",
"      ]. When the viral load was less than 1000 CMV DNA",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      the standard deviation ranges from 0.11 to 0.48 log",
"      <sub>",
"       10",
"      </sub>",
"      . In contrast, when the viral load reached or exceeded 10,000 CMV DNA",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      the standard deviation was consistently at or below 0.15 log",
"      <sub>",
"       10",
"      </sub>",
"      . In a study that compared the COBAS",
"      <span class=\"nowrap\">",
"       AmpliPrep/COBAS",
"      </span>",
"      TaqMan CMV test to the Amplicor test, the former test had a wider linear range and higher sensitivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/20\">",
"       20",
"      </a>",
"      ]. It also has the benefit of using an international standard for quantitation.",
"     </li>",
"     <li>",
"      A study evaluated the performance of a real-time laboratory-developed PCR assay using commercially available analyte specific reagents (Abbott Molecular, Des Plaines, IL) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/16\">",
"       16",
"      </a>",
"      ]. This assay was linear from 2.0 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      to at least 6.0 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      when testing plasma specimens, and the limit of detection was 2.3 log",
"      <sub>",
"       10",
"      </sub>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (200",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      The assay had the greatest precision at higher viral loads.",
"     </li>",
"     <li>",
"      Plasma or whole blood specimens are typically used for CMV load testing. DNA is detected more frequently and viral load values are often higher in whole blood as compared to plasma because both cell free and intracellular viruses are detected. One study showed that viral load values in mo",
"      <sub>",
"       st",
"      </sub>",
"      patients are about 1 log",
"      <sub>",
"       10",
"      </sub>",
"      (10",
"      <sub>",
"       -",
"      </sub>",
"      fold) higher in whole blood compared to plasma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/21\">",
"       21",
"      </a>",
"      ]. Although testing of whole blood specimens is more sensitive than plasma, low levels of CMV DNA in whole blood do not always correlate with active CMV disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these data, and comparisons to the human immunodeficiency virus (HIV)-1 viral load assays, it is likely that viral load changes will need to exceed 0.5 to 0.7 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (eg, three- to fivefold) to represent clinically significant changes in CMV viral replication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until there is adequate standardization of viral load tests, it is important to use the same test, and same clinical sample type (whole blood or plasma), when monitoring patients over time in order to accurately assess changes in viral load [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL UTILITY OF QUANTITATIVE MOLECULAR CMV ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been numerous studies supporting the clinical utility of viral load testing in managing cytomegalovirus (CMV) disease in solid organ transplant recipients. These assays are now used routinely in many transplant centers to diagnose active CMV disease, to screen patients for the use of preemptive antiviral therapy, and to monitor responses to antiviral therapy. Molecular assays offer several advantages over the antigenemia assay including increased stability of the specimen, smaller specimen volume, and the ability to test patients with leukopenia.",
"   </p>",
"   <p>",
"    Studies of solid organ transplant recipients using laboratory-developed quantitative PCR assays have shown a higher viral load in patients with active CMV disease compared to those with asymptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. However, viral load values between the assays were not comparable due to differences in assay design and quantification standards. As a result, the cutoff viral load associated with active CMV disease was different for each study, making it difficult to compare results between the studies. Standardization of viral load values using the international CMV standard will permit data from different studies to be compared and thus provide the advantage of establishing broadly applicable and clinically relevant guidelines for use of viral load assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/10,28\">",
"     10,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Comparison of tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As noted above, the COBAS",
"    <span class=\"nowrap\">",
"     AmpliPrep/COBAS",
"    </span>",
"    TaqMan CMV test uses the international CMV standard and has been approved by the United States Food and Drug Administration for monitoring changes in CMV load in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Molecular assays for the quantification of CMV DNA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis of active CMV disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Currently, CMV load testing can be employed for the rapid diagnosis of active CMV disease and the identification of patients at risk for developing CMV disease. Results can be used to guide decisions about preemptive therapy and to monitor responses to therapy.",
"   </p>",
"   <p>",
"    Several studies have reported on the clinical utility of PCR testing in the diagnosis and monitoring of CMV disease following solid organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/2,14,29,30\">",
"     2,14,29,30",
"    </a>",
"    ]. In most of these studies, CMV infection was defined as a positive laboratory test (culture, PCR, or antigenemia), while CMV disease required clinical symptoms plus a positive laboratory test or",
"    <span class=\"nowrap\">",
"     culture/immunohistochemical",
"    </span>",
"    evidence of CMV on tissue biopsy. These studies have shown that higher viral load levels were detected in patients with symptomatic disease compared to those with asymptomatic infection.",
"   </p>",
"   <p>",
"    The Amplicor PCR test was evaluated in a series of 97 liver transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/14\">",
"     14",
"    </a>",
"    ]. No preemptive therapy was used in the study, but patients with the highest risk of developing CMV disease (donor CMV seropositive, recipient CMV seronegative,",
"    <span class=\"nowrap\">",
"     D+/R-)",
"    </span>",
"    received prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    therapy for 12 weeks. The optimal cutoff for predicting CMV disease was in the range of 2000 to 5000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    of plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/14\">",
"     14",
"    </a>",
"    ], while all patients with a viral load of &gt;20,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    of plasma developed CMV disease. This report also showed that the Amplicor PCR test was as useful as the antigenemia assay in monitoring patients for preemptive ganciclovir therapy.",
"   </p>",
"   <p>",
"    Not only is the level of CMV DNA predictive, but the rate of increase in viral load can also be used to predict patients at risk for CMV disease. In one study, patients with CMV disease had a significantly faster rate of increase in CMV load between the last PCR-negative and first PCR-positive sample than those without CMV disease (0.33 log",
"    <sub>",
"     10",
"    </sub>",
"    versus 0.19 log",
"    <sub>",
"     10",
"    </sub>",
"    <span class=\"nowrap\">",
"     genomes/mL",
"    </span>",
"    daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/31\">",
"     31",
"    </a>",
"    ]. The combination of CMV load in the initial phase of infection and the rate of increase in viral load may help to identify patients at risk for CMV disease.",
"   </p>",
"   <p>",
"    Establishing the appropriate viral load cutoff for initiating preemptive therapy for CMV will likely depend upon a variety of factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assay used",
"     </li>",
"     <li>",
"      Specimen type (eg, plasma, whole blood, leukocytes)",
"     </li>",
"     <li>",
"      Organ transplanted",
"     </li>",
"     <li>",
"      Serostatus of both the recipient and donor",
"     </li>",
"     <li>",
"      Type of immunosuppression",
"     </li>",
"     <li>",
"      Presence of coinfection with other immunomodulating viruses, such as human herpesvirus (HHV)-6",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, CMV infection has been shown to occur more commonly in patients with HHV-6 infection compared to those without HHV-6 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40167?source=see_link\">",
"     \"Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection\"",
"    </a>",
"    .) Additional studies are needed to evaluate all of these factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CMV load assays are also useful in monitoring responses to antiviral therapy in transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral load becomes undetectable several weeks after initiating therapy using the Amplicor PCR test [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/12-14\">",
"       12-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with documented",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      resistance have persistently elevated viral load values while on therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study documented that a persistently detectable viral load following two weeks of therapy was associated with relapsing CMV infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Viral load kinetics can also be useful for identifying patients who are more likely to develop recurrent CMV disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/33\">",
"     33",
"    </a>",
"    ]. In one study, the mean time to viral clearance was significantly longer in patients with recurrent CMV disease compared to those without recurrence (mean 33.8 days versus 17.2 days, respectively). Viral load half-life was 8.8 days in patients with recurrence compared to 3.17 days in patients without recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/33\">",
"     33",
"    </a>",
"    ]. Monitoring viral load kinetics allows for the identification of patients at risk for recurrent CMV disease at a very early stage in treatment, thus allowing for optimization of antiviral therapy.",
"   </p>",
"   <p>",
"    As noted above, the COBAS",
"    <span class=\"nowrap\">",
"     AmpliPrep/COBAS",
"    </span>",
"    TaqMan CMV test has been approved by the United States Food and Drug Administration for monitoring changes in CMV load in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Molecular assays for the quantification of CMV DNA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPECIAL REQUIREMENTS AND STORAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Amplicor polymerase chain reaction (PCR) test requires 200 microL of plasma or 1x10",
"    <sup>",
"     6",
"    </sup>",
"    leukocytes. The specimen type (plasma, leukocytes, whole blood) and volume vary among laboratory-developed assays, although most use between 200 and 500 microL of plasma or whole blood. Cytomegalovirus (CMV) DNA is stable in whole blood and plasma for up to five days when stored at 4&deg;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/13,34\">",
"     13,34",
"    </a>",
"    ] and for three to four days when stored at room temperature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. EDTA is the preferred anticoagulant for quantitative CMV PCR assays. One study has shown that once plasma is separated from whole blood, the plasma DNA is stable for 14 days at 4&deg;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44230/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative stability of CMV DNA in whole blood and the lower specimen volume are advantages for the molecular assays compared to the antigenemia assay, which requires 3 to 5 mL of blood and processing of blood within eight hours of collection. In addition, molecular assays can utilize plasma specimens from patients with low leukocyte counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AVAILABILITY AND COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) load assays are available from reference laboratories and clinical laboratories, usually those that provide services for transplant centers. Since viral load values may not be comparable among different laboratory-developed assays, it is important to use the same assay when monitoring a patient over time. The cost of CMV load assays varies from $120 to $300 per test. Currently, there are no FDA-approved quantitative CMV molecular assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There have been numerous studies supporting the clinical utility of viral load testing in managing cytomegalovirus disease in solid organ transplant recipients. These assays are now used routinely in many transplant centers to diagnose active disease cytomegalovirus disease, to screen patients for the use of preemptive antiviral therapy, and to monitor response to antiviral therapy. Molecular assays offer several advantages over the antigenemia assay including increased stability of the specimen, smaller specimen volume, and the ability to test patients with leukopenia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical utility of quantitative molecular CMV assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The availability of an international cytomegalovirus standard will improve agreement in viral load values among assays and should allow a better understanding of the viral load values that predict the development of disease. Several commercial assays under development and in clinical trials should further help standardize testing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Comparison of tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Griffiths PD, Emory VC. Cytomegalovirus. In: Clinical Virology, Richman DD, Whitley RJ, Hayden FG (Eds), Churchill Livingstone, New York City 1997. p.445.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/2\">",
"      Aitken C, Barrett-Muir W, Millar C, et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999; 37:2804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/3\">",
"      Gerna G, Zipeto D, Parea M, et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 1991; 164:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/4\">",
"      Tanabe K, Tokumoto T, Ishikawa N, et al. Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 1997; 64:1721.",
"     </a>",
"    </li>",
"    <li>",
"     Roche Molecular Diagnostics. COBAS AmpliPrep/COBAS TaqMan CMV test. file://molecular.roche.com/assays/Pages/COBASAmpliPrepCOBASTaqManCMVTest.aspx (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration News Release. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310691.htm (Accessed on July 09, 2012).",
"    </li>",
"    <li>",
"     Roche Molecular Diagnostics. COBAS AMPLICOR CMV MONITOR test. file://molecular.roche.com/assays/Pages/COBASAMPLICORCMVMONITORTest.aspx (Accessed on July 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/8\">",
"      Caliendo AM, Schuurman R, Yen-Lieberman B, et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus DNA in plasma. J Clin Microbiol 2001; 39:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/9\">",
"      Pang XL, Fox JD, Fenton JM, et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009; 9:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/10\">",
"      Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 2012; 54:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/11\">",
"      Tong CY, Cuevas LE, Williams H, Bakran A. Comparison of two commercial methods for measurement of cytomegalovirus load in blood samples after renal transplantation. J Clin Microbiol 2000; 38:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/12\">",
"      Caliendo AM, St George K, Allega J, et al. Distinguishing cytomegalovirus (CMV) infection and disease with CMV nucleic acid assays. J Clin Microbiol 2002; 40:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/13\">",
"      Caliendo AM, St George K, Kao SY, et al. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients. J Clin Microbiol 2000; 38:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/14\">",
"      Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/15\">",
"      Caliendo AM, Yen-Lieberman B, Baptista J, et al. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol 2003; 41:3509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/16\">",
"      Caliendo AM, Ingersoll J, Fox-Canale AM, et al. Evaluation of real-time PCR laboratory-developed tests using analyte-specific reagents for cytomegalovirus quantification. J Clin Microbiol 2007; 45:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/17\">",
"      Razonable RR, Brown RA, Espy MJ, et al. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems. J Clin Microbiol 2001; 39:4472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/18\">",
"      Razonable RR, Brown RA, Wilson J, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 2002; 73:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/19\">",
"      Hirsch HH, Lautenschlager I, Pinsky BA, et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013; 56:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/20\">",
"      Kerschner H, Bauer C, Schlag P, et al. Clinical evaluation of a fully automated CMV PCR assay. J Clin Virol 2011; 50:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/21\">",
"      Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011; 91:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/22\">",
"      Smith TF, Espy MJ, Mandrekar J, et al. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis 2007; 45:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/23\">",
"      Cope AV, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/24\">",
"      Ferreira-Gonzalez A, Fisher RA, Weymouth LA, et al. Clinical utility of a quantitative polymerase chain reaction for diagnosis of cytomegalovirus disease in solid organ transplant patients. Transplantation 1999; 68:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/25\">",
"      Roberts TC, Brennan DC, Buller RS, et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998; 178:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/26\">",
"      Weinberg A, Hodges TN, Li S, et al. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000; 38:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/27\">",
"      Hassan-Walker AF, Kidd IM, Sabin C, et al. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/28\">",
"      Caliendo AM. The long road toward standardization of viral load testing for cytomegalovirus. Clin Infect Dis 2013; 56:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/29\">",
"      Sia IG, Wilson JA, Espy MJ, et al. Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation. J Clin Microbiol 2000; 38:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/30\">",
"      Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/31\">",
"      Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/32\">",
"      Humar A, Malkan G, Moussa G, et al. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000; 181:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/33\">",
"      Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186:829.",
"     </a>",
"    </li>",
"    <li>",
"     Yen-Lieberman, B, Starkey, C, Kohn, D. The effect of storage conditions on the stability of CMV DNA in whole blood and plasma specimens. Abstract C-143, American Society of Microbiology 101st Meeting. Orlando, FL 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/35\">",
"      Sch&auml;fer P, Tenschert W, Gutensohn K, Laufs R. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. J Clin Microbiol 1997; 35:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44230/abstract/36\">",
"      Abdul-Ali D, Kraft CS, Ingersoll J, et al. Cytomegalovirus DNA stability in EDTA anti-coagulated whole blood and plasma samples. J Clin Virol 2011; 52:222.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8305 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44230=[""].join("\n");
var outline_f43_12_44230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR ASSAYS FOR THE QUANTIFICATION OF CMV DNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Comparison of tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL UTILITY OF QUANTITATIVE MOLECULAR CMV ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis of active CMV disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring response to therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPECIAL REQUIREMENTS AND STORAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AVAILABILITY AND COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/14/40167?source=related_link\">",
"      Virology, pathogenesis, and epidemiology of human herpesvirus 6 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_12_44231="Simvastatin: Pediatric drug information";
var content_f43_12_44231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Simvastatin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"    see \"Simvastatin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11541?source=see_link\">",
"    see \"Simvastatin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F12889403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      HMG-CoA Reductase Inhibitors and Risk of Increased Blood Glucose Concentrations and Diabetes",
"     </span>",
"     <span class=\"collapsible-date\">",
"      January 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has notified healthcare professionals of updates to the product monographs of HMG-CoA reductase inhibitors (aka, &ldquo;statins&rdquo;) marketed in Canada regarding the risk of increased blood glucose concentrations and a small increased risk of diabetes mellitus following administration of these agents. The risk appears to be greatest in patients already at risk for diabetes (eg, patients with increased blood glucose concentration, hypertriglyceridemia, obesity, hypertension).  However, Health Canada continues to acknowledge that the benefits of statin therapy far outweigh the risk of dysglycemia. It is recommended that clinicians carefully monitor the use of statins in patients at high risk of developing diabetes mellitus.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/16949a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Simvastatin and Dose-Related Myopathy: Health Canada Issues Notice",
"     </span>",
"     <span class=\"collapsible-date\">",
"      November 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada, in conjunction with Merck Canada Inc, has issued notice to Canadian healthcare professionals regarding increased risks of myopathy associated with high-dose (80 mg/day) simvastatin (Zocor&reg;).  The simvastatin Canadian product monograph recommends limiting the dose to &le;40 mg/day; an alternative treatment should be used for patients unable to reach their LDL-C goal with this dosage recommendation. Higher doses (80 mg/day) of simvastatin are restricted to patients requiring chronic use and without evidence of myopathy or who are at high risk of cardiovascular complications and unable to tolerate other statins. Specific recommendations regarding simvastatin use and dosage with concomitant medications (eg, verapamil, amiodarone, amlodipine, fusidic acid) and grapefruit juice are also included in the product labeling.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at  file://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/zocor_hpc-cps-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zocor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Simvastatin&reg;;",
"     </li>",
"     <li>",
"      Ava-Simvastatin;",
"     </li>",
"     <li>",
"      CO Simvastatin;",
"     </li>",
"     <li>",
"      Dom-Simvastatin;",
"     </li>",
"     <li>",
"      JAMP-Simvastatin;",
"     </li>",
"     <li>",
"      Mint-Simvastatin;",
"     </li>",
"     <li>",
"      Mylan-Simvastatin;",
"     </li>",
"     <li>",
"      Nu-Simvastatin;",
"     </li>",
"     <li>",
"      PHL-Simvastatin;",
"     </li>",
"     <li>",
"      PMS-Simvastatin;",
"     </li>",
"     <li>",
"      Q-Simvastatin;",
"     </li>",
"     <li>",
"      RAN&trade;-Simvastatin;",
"     </li>",
"     <li>",
"      ratio-Simvastatin;",
"     </li>",
"     <li>",
"      Riva-Simvastatin;",
"     </li>",
"     <li>",
"      Sandoz-Simvastatin;",
"     </li>",
"     <li>",
"      Simvastatin-Odan;",
"     </li>",
"     <li>",
"      Taro-Simvastatin;",
"     </li>",
"     <li>",
"      Teva-Simvastatin;",
"     </li>",
"     <li>",
"      Zocor&reg;;",
"     </li>",
"     <li>",
"      ZYM-Simvastatin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HMG-CoA Reductase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"      see \"Simvastatin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Heterozygous familial hypercholesterolemia:",
"     </b>",
"     Adolescents 10-17 years: 10 mg once daily in the evening; may increase dose in intervals of 4 weeks or more to a maximum of 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hyperlipidemia:",
"     </b>",
"     Limited data in 32 children (&lt;17 years of age) enrolled in compassionate use study (Ducobu, 1992):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;10 years: 5 mg once daily in the evening increasing to 10 mg once daily after 4 weeks and to 20 mg once daily after 8 weeks as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;10 years: 10 mg once daily in the evening increasing to 20 mg once daily after 6 weeks and to 40 mg once daily after 12 weeks as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A lower, conservative dosing regimen may be necessary in patient populations predisposed to myopathy including patients of Chinese descent or those concurrently receiving other lipid-lowering agents (eg, niacin, fibric acid derivatives), amiodarone, amlodipine, ranolazine, verapamil (see the following conservative, maximum adult doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be individualized according to the baseline LDL-cholesterol levels, the recommended goal of therapy, and the patient's response; adjustments should be made at intervals of 4 weeks or more; doses may need adjusted based on concomitant medications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing limitation: Simvastatin 80 mg is limited to patients that have been taking this dose for &gt;12 consecutive months without evidence of myopathy and are not currently taking or beginning to take a simvastatin dose-limiting or contraindicated interacting medication. If patient is unable to achieve LDL-C goal using the 40 mg dose of simvastatin, increasing to 80 mg dose is not recommended. Instead, switch patient to an alternative LDL-C-lowering treatment providing greater LDL-C reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of cardiovascular events, hyperlipidemias:",
"     </b>",
"     Oral: 20-40 mg once daily in the evening (range: 5-40 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients requiring only moderate reduction of LDL-cholesterol: May be started at 10 mg once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients requiring reduction of &gt;45% in low-density lipoprotein (LDL) cholesterol: May be started at 40 mg once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients with CHD or at high risk for cardiovascular events (patients with diabetes, PVD, history of stroke, or other cerebrovascular disease): Dosing should be started at 40 mg once daily in the evening; simvastatin should be started simultaneously with diet therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Homozygous familial hypercholesterolemia:",
"     </b>",
"     40 mg once daily in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients receiving concomitant diltiazem or verapamil:",
"     </b>",
"     Adults: Dose should not exceed 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in patients receiving concomitant amiodarone, amlodipine, or ranolazine:",
"     </b>",
"     Adults: Dose should not exceed 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in Chinese patients on niacin doses &ge;1 g/day:",
"     </b>",
"     Use caution with simvastatin doses exceeding 20 mg/day; because of an increased risk of myopathy, do not increase simvastatin dose to 80 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild to moderate renal impairment: No dosage adjustment necessary; simvastatin does not undergo significant renal excretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Severe renal impairment: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute; Initial: 5 mg/day with close monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alternative recommendation: No dosage adjustment necessary for any degree of renal impairment (Aronoff, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zocor&reg;: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken without regard to meals. Administration with the evening meal or at bedtime has been associated with somewhat greater LDL-C reduction",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets should be stored in well closed containers at temperatures between 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hyperlipidemia: Adjunct to dietary therapy to decrease elevated serum total (total-C) and low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo-B) in pediatric patients with heterozygous familial hypercholesterolemia (FDA approved in boys and postmenarchal girls 10-17 years); adjunct to dietary therapy to decrease elevated serum total-C, LDL-C, apo-B, and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous, familial, and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) (FDA approved in adults); reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type IV) (FDA approved in adults); reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson Type III) (FDA approved in adults); reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Secondary prevention of cardiovascular events in hypercholesterolemic patients with established coronary heart disease (CHD) or at high risk for CHD: To reduce cardiovascular morbidity (myocardial infarction, coronary/noncoronary revascularization procedures) and mortality; to reduce the risk of stroke (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F221358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Simvastatin may be confused with atorvaSTATin, nystatin, pitavastatin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zocor&reg; may be confused with Cozaar&reg;, Lipitor&reg;, Zoloft&reg;, ZyrTEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cardin [Poland] may be confused with Cardem brand name for celiprolol [Spain]; Cardene brand name for nicardipine [U.S., Great Britain, Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F221356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Eczema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, gastritis, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased (&gt;3 x ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (&gt;3 x normal), myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, upper respiratory infections",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, alopecia, amnesia (reversible), anaphylaxis, anemia, angioedema, arthralgia, arthritis, blood glucose increased, chills, cognitive impairment (reversible), confusion (reversible), depression, dermatomyositis, diabetes mellitus (new onset), diarrhea, dizziness, dryness of skin/mucous membranes, dyspepsia, dyspnea, eosinophilia, erythema multiforme, ESR increased, fever, flatulence, flushing, glycosylated hemoglobin (Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ) increased, GGT increased, hemolytic anemia, hepatic failure, hepatitis, hypersensitivity reaction, jaundice, leukopenia, malaise, memory disturbance (reversible), memory impairment (reversible), muscle cramps, nail changes, nodules, pancreatitis, paresthesia, peripheral neuropathy, photosensitivity, polymyalgia rheumatica, positive ANA, pruritus, purpura, rash, rhabdomyolysis, skin discoloration, Stevens-Johnson syndrome, systemic lupus erythematosus-like syndrome, thrombocytopenia, toxic epidermal necrolysis, urticaria, vasculitis, vomiting, weakness",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Additional class-related events or case reports (not necessarily reported with simvastatin therapy): Alteration in taste, anorexia, anxiety, bilirubin increased, cataracts, cholestatic jaundice, cirrhosis, decreased libido, depression, erectile dysfunction/impotence, facial paresis, fatty liver, fulminant hepatic necrosis, gynecomastia, hepatoma, hyperbilirubinemia, immune-mediated necrotizing myopathy (IMNM), impaired extraocular muscle movement, increased CPK (&gt;10 x normal), interstitial lung disease, ophthalmoplegia, peripheral nerve palsy, psychic disturbance, renal failure (secondary to rhabdomyolysis), thyroid dysfunction, tremor, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to simvastatin or any component; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy; breast-feeding; concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, HIV protease inhibitors, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin), cyclosporine, danazol, and gemfibrozil",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Persistent increases in serum transaminases have occurred; liver function must be monitored by laboratory assessment at the initiation of therapy and periodically thereafter for the first year of treatment or until one year after the last elevation in dose. Use with caution in patients who consume substantial quantities of alcohol or have a previous history of liver disease. Use with caution in patients with diabetes mellitus and renal impairment (may be at increased risk for developing rhabdomyolysis)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rhabdomyolysis with acute renal failure has occurred. Risk is dose-related and is increased with concurrent use of lipid-lowering agents which may also cause rhabdomyolysis (gemfibrozil, other fibric acid derivatives, or niacin at doses &ge;1 g/day), and concurrent use of other interacting medications (eg, amiodarone, grapefruit juice in large quantities, verapamil). Monitor closely if used with other drugs associated with myopathy (eg, colchicine). Assess the risk versus benefit when combining any of these drugs with simvastatin. Concomitant use of high-dose simvastatin (80 mg) with niacin &ge;1 g/day may increase risk of myopathy in Chinese patients. A lowered dosage of simvastatin is recommended when used with medications which may increase risk of rhabdomyolysis. Advise patients to promptly report any unexplained muscle pain, tenderness, or weakness. Temporarily discontinue simvastatin in any patient experiencing an acute or serious condition predisposing to renal failure due to the potential risk of developing rhabdomyolysis.",
"     <b>",
"      High dose (80 mg) is limited to patients who  have been taking this dose for &gt;12 consecutive months without evidence of myopathy and are not currently taking or beginning to take a simvastatin dose-limiting or contraindicated interacting medication.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F221344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (weak), CYP2C9 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Dose of HMG-CoA reductase inhibitor may need to be reduced (limit simvastatin adult maximum dose to 20 mg/day, limit lovastatin adult maximum dose to 40 mg/day).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AmLODIPine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of amlodipine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day (for adults).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors. More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors. Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Concurrent use of simvastatin with danazol is contraindicated.  Initiate lovastatin at an adult maximum dose of 10 mg/day, and do not exceed 20 mg/day, when danazol is given concomitantly.  Fluvastatin, pravastatin and rosuvastatin may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DAPTOmycin: HMG-CoA Reductase Inhibitors may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diltiazem: May increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem. Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Simvastatin. Management: Limit simvastatin to a max of 10 mg/day (in adults). Increase monitoring for signs of simvastatin toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use of HMG-CoA reductase inhibitors (statins) with fusidic acid if possible.  If treatment with fusidic acid is necessary, consider temporarily stopping the statin.  With any concurrent use monitor patients closely for statin toxicity.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Gemfibrozil may increase the serum concentration of Simvastatin. Concentrations of the active simvastatin acid metabolite may also be increased by gemfibrozil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider avoiding concurrent use of GFJ (especially larger amounts) with lovastatin, simvastatin, or atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May increase the serum concentration of Simvastatin. Specifically, Simvastatin lactone concentrations may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: HMG-CoA Reductase Inhibitors may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Simvastatin. Management: Reduce the recommended simvastatin dose by 50%. Generally, limit the maximum adult simvastatin dose to 20 mg/day. A 40 mg/day dose can be considered in patients who previously received 80 mg/day for at least a year without evidence of muscle toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of HMG-CoA Reductase Inhibitors. Management: Avoid lovastatin or simvastatin with erythro-, clarithro-, or telithromycin. Limit pitavastatin to a 1 mg/day maximum adult dose with erythromycin.  Atorvastatin dose adjustments may be required. Increase monitoring for toxicity with any such combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of Simvastatin. Management: Avoid simvastatin during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors. Management: This is of greatest concern with niacin doses of 1 g or greater daily.  Avoid simvastatin 80 mg in combination with niacin 1 g or greater in Chinese patients. Canadian labeling contraindicates use of niacin with rosuvastatin 40 mg.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: HMG-CoA Reductase Inhibitors may enhance the hepatotoxic effect of Pazopanib. Specifically, the risk for increased serum transaminase concentrations may be increased.  Management: Simvastatin is specifically implicated in this interaction.  There is a lack of data regarding the risk with other statins, but caution appears warranted with any statins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: May increase the serum concentration of Simvastatin. Management: Avoid the concurrent use of ranolazine with simvastatin when possible.  If used together, avoid doses of simvastatin greater than 20 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors. Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: May decrease the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: May increase the serum concentration of Simvastatin. Management: Avoid using doses of simvastatin greater than 40 mg/day with ticagrelor.  This specific recommendation is found in the U.S. prescribing information but not in the Canadian product monograph.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trabectedin: HMG-CoA Reductase Inhibitors may enhance the myopathic (rhabdomyolysis) effect of Trabectedin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Simvastatin. Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): HMG-CoA Reductase Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1062128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Simvastatin serum concentration may be increased when taken with large quantities (&gt;1 quart/day) of grapefruit juice; avoid concurrent use",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1792946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy. Administer to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards. If pregnancy occurs during treatment, discontinue simvastatin immediately.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Creatine phosphokinase levels due to possibility of myopathy; serum cholesterol (total and fractionated); baseline CPK (recheck CPK in any patient with symptoms suggestive of myopathy). Obtain liver function tests prior to initiation, dose, and thereafter when clinically indicated. Patients with elevated transaminase levels should have a second (confirmatory) test and frequent monitoring until values normalize. Discontinue if increase in ALT/AST is persistently &gt;3 times ULN. Monitor LDL-C at intervals no less than 4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Simvastatin is a methylated derivative of lovastatin that acts by competitively inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: &gt;3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: After 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     LDL-C reduction: 20-40 mg/day: 35% to 41% (for each doubling of this dose, LDL-C is lowered &sim;6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Average HDL-C increase: 5% to 15%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Average triglyceride reduction: 7% to 30%",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Although 85% is absorbed following administration, &lt;5% reaches the general circulation due to an extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1.3-2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 13% excreted in urine and 60% in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11541?source=see_link\">",
"      see \"Simvastatin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight. Report severe and unresolved gastric upset, any vision changes, muscle pain and weakness, changes in color of urine or stool, yellowing of skin or eyes, and any unusual bruising. Female patients of childbearing age must be counseled to use 2 effective forms of contraception simultaneously, unless absolute abstinence is the chosen method; this drug may cause severe fetal defects.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Nutrition, &ldquo;Cholesterol in Childhood,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(1 Pt 1):141-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44231/abstract-text/11345978/pubmed\" id=\"11345978\" target=\"_blank\">",
"        11345978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, &ldquo;National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(3 Pt 2):525-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44231/abstract-text/ 1538956 /pubmed\" id=\" 1538956 \" target=\"_blank\">",
"        1538956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44231/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeJongh S, et al, &ldquo;Efficacy, Safety, and Tolerability of Simvastatin in Children With Familial Hypercholesterolemia,&rdquo;",
"      <i>",
"       Clin Drug Invest",
"      </i>",
"      , 2002, 22(8): 533-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ducobu J, Brasseur D, Chaudron JM, et al, &ldquo;Simvastatin Use in Children,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 339(8807):1488.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44231/abstract-text/1351171/pubmed\" id=\"1351171\" target=\"_blank\">",
"        1351171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duplaga BA, &ldquo;Treatment of Childhood Hypercholesterolemia With HMG-CoA Reductase Inhibitors,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(11):1224-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44231/abstract-text/ 10573325 /pubmed\" id=\" 10573325 \" target=\"_blank\">",
"        10573325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grundy SM, Cleeman JI, Merz CN, et al, &ldquo;Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(2):227-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44231/abstract-text/15249516 /pubmed\" id=\"15249516 \" target=\"_blank\">",
"        15249516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/12/44231/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12792 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.81.197.98-FF1ADEC9A5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44231=[""].join("\n");
var outline_f43_12_44231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12889403\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221302\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221303\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062117\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062110\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221278\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221263\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062121\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062113\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062120\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221358\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221356\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062125\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062109\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062108\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221344\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221272\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062128\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221274\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1792946\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062116\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062107\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062123\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062124\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062115\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=related_link\">",
"      Simvastatin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/17/11541?source=related_link\">",
"      Simvastatin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_12_44232="Chemotherapy-induced alopecia";
var content_f43_12_44232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy-induced alopecia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44232/contributors\">",
"     Aimee S Payne, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44232/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44232/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44232/contributors\">",
"     Maria Hordinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44232/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/12/44232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair loss is a transient but often psychologically devastating consequence of cancer chemotherapy. For some patients, the emotional trauma may be so severe as to lead to discontinuing or refusing treatment that might otherwise be beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomy and physiology of hair growth, the effects of chemotherapy, and possible means for preventing alopecia are discussed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hair fiber is the product of the hair follicle and is a complex keratinized structure consisting of a cuticle, cortex and medulla. The hair follicle is composed of three main parts when viewed in longitudinal section (",
"    <a class=\"graphic graphic_figure graphicRef53952 \" href=\"mobipreview.htm?30/38/31332\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lower portion, which extends from the base of the hair follicle to the insertion of the arrector pili muscle. This lower portion, in turn, is comprised of several major components:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The hair bulb, which contains the dermal papilla and hair matrix. The dermal papilla controls the number of matrix cells, which determines hair fiber size [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/6\">",
"       6",
"      </a>",
"      ]. Melanocytes, which are responsible for hair color, are present among the matrix cells of the hair bulb.",
"     </li>",
"     <li>",
"      The hair itself, consisting of medulla, cortex, and hair cuticle (inside to outside).",
"     </li>",
"     <li>",
"      The inner root sheath, which consists of the inner root sheath cuticle, Huxley layer, and Henle's layer (inside to outside). The inner root sheath is rigid, with its shape determining whether hair is curly or straight.",
"     </li>",
"     <li>",
"      The outer root sheath.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Damage to the lower portion of the hair follicle, as occurs in autoimmune alopecia areata, can result in a nonscarring alopecia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The middle portion (isthmus), which extends from the insertion of the arrector pili muscle to the entrance of the sebaceous duct. This portion contains the \"bulge\" of the hair follicle, where epithelial stem cells reside [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/7\">",
"       7",
"      </a>",
"      ]. Damage to the bulge of the hair follicle results in irreversible scarring alopecia, as is seen clinically in disorders such as discoid lupus and lichen planopilaris.",
"     </li>",
"     <li>",
"      The upper portion (infundibulum), which extends from the entrance of the sebaceous duct to the follicular orifice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Throughout life, the hair follicle undergoes periods of cyclic growth (anagen, lasting two to eight years), regression (catagen, two to three weeks), and dormancy (telogen, three to four months), after which time the hair is shed (also known as exogen). Approximately 80 to 90 percent of follicles at any given time are in the active growth phase (anagen). During anagen, mitotically active matrix cells in the hair bulb differentiate and divide, resulting in a rate of hair growth of approximately 0.35 mm per day. Approximately 5 to 10 percent of follicles are in telogen (dormancy), during which all mitotic activity is arrested. The remaining 1 to 3 percent are in catagen, the involution phase. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13846?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonscarring hair loss\", section on 'Hair growth cycle'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The final step of the hair cycle, exogen, is when the hair is released from the follicle. The scalp is estimated to contain on average 100,000 hairs, of which 100 to 150 are lost daily as part of the normal hair cycle. This loss typically occurs after washing and brushing the hair, so patients who wash their hair less frequently may note a greater number of hairs falling out at each instance.",
"   </p>",
"   <p>",
"    Multiple signaling molecules have been implicated in the initial development and subsequent cycling of the hair follicle, including Wnt, Sonic Hedgehog, notch, and bone morphogenic proteins, among others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/8\">",
"     8",
"    </a>",
"    ]. In a mouse model of chemotherapy-induced alopecia, transient overexpression of Sonic hedgehog accelerated hair follicle regrowth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS OF CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytotoxic chemotherapy attacks rapidly dividing cells in the body, including the dividing hair matrix cells. This can result in hair loss by either of two mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thinning of the hair shaft can occur at the time of maximal chemotherapy effect, resulting in Pohl-Pinkus constrictions. As a result, the hair shaft may break at the follicular orifice.",
"     </li>",
"     <li>",
"      If matrix proliferation is severely inhibited, the hair may separate at the bulb and shed, a process referred to as anagen effluvium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hair may be completely lost in a short time, as is typically the case for high dose regimens used in the setting of stem cell transplantation, or it may be gradually lost over a period of several weeks, as often occurs with the use of cyclic chemotherapy regimens. Additionally, chemotherapeutic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    may temporarily affect the follicle melanocytes, resulting in a depigmented band of hair (the so-called \"flag sign\"). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Hair'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability of individual agents to cause hair loss depends upon the route, dose, and schedule of drug administration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose, intermittent, intravenous chemotherapy regimens are associated with a high incidence of complete alopecia.",
"     </li>",
"     <li>",
"      Low-dose therapy, oral administration, and weekly regimens are less likely to induce total or complete alopecia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,2\">",
"       1,2",
"      </a>",
"      ]. As an example, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      almost universally causes alopecia while oral regimens are less likely to do so.",
"     </li>",
"     <li>",
"      Combination chemotherapy regimens are more likely to result in alopecia than are single agents. Unfortunately, the incidence of alopecia with common regimens has been inconsistently documented in the literature (",
"      <a class=\"graphic graphic_table graphicRef80094 \" href=\"mobipreview.htm?29/57/30620\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link\">",
"       \"Acute side effects of adjuvant chemotherapy for early stage breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of the commonly used single cytotoxic agents, those most likely to cause complete alopecia include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    . Hair loss is less common or incomplete with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/42/28325?source=see_link\">",
"     eribulin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , and the vinca alkaloids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23126237\">",
"    <span class=\"h2\">",
"     Effects of molecularly-targeted agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small molecule inhibitors of the epidermal growth factor receptor (EGFR) as well as monoclonal antibodies targeting the EGFR can induce a constellation of cutaneous symptoms that include an acneiform rash, abnormal hair growth, pruritus, and dry skin; together, this symptom complex is referred to by the acronym PRIDE (Papulopustules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paronychia, Regulatory abnormalities of hair growth, Itching, Dryness due to Epidermal growth factor receptor inhibitors). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H2#H2\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'EGFR signal transduction inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, diffuse alopecia is described as a side effect of these drugs (4 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ). The alopecia is typically non-scarring and therefore reversible. However, at least two reports describe patients on long-term therapy who developed scarring alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Interestingly, mice with a targeted deletion in the EGFR gradually develop scarring alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diffuse, reversible alopecia is also described in up to 50 percent of patients receiving treatment with orally active multitargeted tyrosine kinase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/13-17\">",
"     13-17",
"    </a>",
"    ] and in 65 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/59/18357?source=see_link\">",
"     vismodegib",
"    </a>",
"    , an orally active agent approved for advanced basal cell cancer that inhibits sonic hedgehog signaling through competitive antagonist binding of the cell surface receptor smoothened. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H7#H7\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Small molecule kinase signal transduction inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=see_link&amp;anchor=H7#H7\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\", section on 'Vismodegib'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy-induced alopecia most commonly affects scalp hair. However, axillary and pubic hair, and even the eyebrows and eyelashes may be lost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H217665997\">",
"    <span class=\"h2\">",
"     Reversibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because chemotherapy effects are typically specific for proliferating cells which reside in the bulb, sparing the quiescent stem cells in the bulge that are responsible for reinitiating follicle growth, hair loss from chemotherapy is usually completely reversible. The hair follicle resumes normal cycling within a few weeks of treatment cessation, and visible regrowth becomes apparent within three to six months. The new hair frequently has different characteristics from the original; 65 percent of patients experience a graying, rejuvenating, curling, or straightening effect, which is likely due to differential effects of chemotherapy on hair follicle melanocytes and inner root sheath epithelia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Permanent alopecia following chemotherapy is rare; most cases have followed the use of high-dose chemotherapy (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) and hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. However, there are isolated case reports of permanent alopecia after standard dose chemotherapy for breast cancer (particularly with taxanes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/22-24\">",
"     22-24",
"    </a>",
"    ], and germ cell tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]; and long-term use of EGFR inhibitors can also cause permanent alopecia. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy and physiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The impact of hair loss and potential alternative chemotherapy approaches should be discussed with each patient",
"    <strong>",
"     before",
"    </strong>",
"    the initiation of therapy that may lead to alopecia. This preemptive approach is important for minimizing the emotional distress associated with hair loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Quantitation of alopecia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alopecia grading scale for treatment-related alopecia is provided in the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absent (grade 0)",
"     </li>",
"     <li>",
"      Mild (grade 1) &ndash; Hair loss of &lt;50 percent of normal for that individual that is not obvious from a distance but only on close inspection; a different hair style may be needed to cover the hair loss but it does not require a wig or hair piece.",
"     </li>",
"     <li>",
"      Severe (grade 2) &ndash; Hair loss of &ge;50 percent for that individual that is readily apparent to others; a wig or hair piece is necessary if the patient desires to completely camouflage the hair loss; associated with psychosocial impact.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVENTION OF ALOPECIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic approaches include physically decreasing the amount of drug delivered to the dividing hair bulb by reducing scalp blood flow and pharmacologic or biologic interventions to block the effects of the chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Decreased drug delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two physical mechanisms to reduce the amount of chemotherapy reaching the scalp, either with a tourniquet to temporarily obstruct blood flow or by inducing scalp hypothermia that causes vasoconstriction. To be effective, both methods require the use of a chemotherapy agent with a short half-life and rapid clearance of the drug and its metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Scalp tourniquet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scalp tourniquet consists of a pneumatic device placed around the hairline during chemotherapy infusion and inflated to a pressure greater than the systolic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/2\">",
"     2",
"    </a>",
"    ]. Several studies have found scalp tourniquets to be effective for preventing hair loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/2,4,27\">",
"     2,4,27",
"    </a>",
"    ]. However, these studies utilized different techniques with variation in chemotherapy regimens, tourniquet pressure, sample size, and criteria to assess alopecia, rendering the data difficult to interpret. Side effects include headache and varying degrees of nerve compression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Scalp hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scalp hypothermia causes vasoconstriction of blood vessels and limits temperature dependent absorption of chemotherapeutic drugs by decreasing the metabolic rate of the hair follicle, thereby inhibiting cellular uptake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,28-30\">",
"     1,28-30",
"    </a>",
"    ]. This requires a scalp temperature of less than 24&ordm;C. Side effects include patient discomfort from the heavy caps, cumbersome units, and messiness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,4,28,31-33\">",
"     1,4,28,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The drugs best suited to this approach include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , actinomycin D and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    . Success with combination regimens such as intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (CMF) has been reported, but this approach failed with the combination of doxorubicin plus cyclophosphamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results of many studies are difficult to interpret secondary to use of multiple cooling systems (ice turban, gel packs, cool caps, thermocirculator, room air conditioner), variable chemotherapy regimens (single versus combined agents), small study populations, and varying definitions of alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. Nevertheless, at least three randomized controlled trials suggest significantly less hair loss with scalp hypothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/27,34,38,39\">",
"     27,34,38,39",
"    </a>",
"    ]. Between 50 and 80 percent of patients have a good to excellent response with this therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,27,34,38,40,41\">",
"     1,27,34,38,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scalp hypothermia may not be as effective in patients with liver dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,2,4,28,30,33,38\">",
"     1,2,4,28,30,33,38",
"    </a>",
"    ]. This is likely related to delayed drug metabolism, thereby allowing persistence of therapeutic drug levels beyond the protective period.",
"   </p>",
"   <p>",
"    Some investigators have raised concerns regarding the possibility of scalp metastasis in association with scalp hypothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1,2,27-29,33,38,42\">",
"     1,2,27-29,33,38,42",
"    </a>",
"    ]. As an example, one group reported the outcome of a patient with mycosis fungoides who used a cooling cap to prevent alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/42\">",
"     42",
"    </a>",
"    ]. Following chemotherapy, he developed recurrent disease limited to the scalp. Subsequent treatment without a cooling device resulted in complete clinical remission.",
"   </p>",
"   <p>",
"    However, the clinical significance of these findings is unclear in patients with solid tumors. In one study of 61 patients with disseminated breast cancer receiving chemotherapy who used a cooling cap, one patient with underlying liver dysfunction developed cutaneous scalp metastasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/28\">",
"     28",
"    </a>",
"    ]. In contrast, three separate series, either entirely or predominantly consisting of patients receiving adjuvant treatment for breast cancer reported no increased frequency of scalp metastases in the patients who were treated in conjunction with a scalp cooling device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/29,41,43\">",
"     29,41,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These case reports suggest that cooling devices may be contraindicated in patients with circulating tumor cells (eg, lymphoma, leukemia) or in those with liver dysfunction resulting in prolonged drug half-lives. They should be used with caution in patients with breast carcinoma, especially in the setting of adjuvant therapy, as well as other carcinomas associated with risk for cutaneous metastases, such as lung, kidney, stomach, colon, and uterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary studies have suggested that a variety of both small molecules and biologic agents may reduce or prevent alopecia by protecting the hair bulb from the damaging effects of chemotherapy. Unfortunately, none of these agents have demonstrated adequate activity in large, randomized clinical trials to justify their general usage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Topical minoxidil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"     Minoxidil",
"    </a>",
"    is thought to modify the hair cycle by prolonging the anagen phase. It may also increase hair follicle size, thereby counteracting the miniaturization of the hair follicle that is the characteristic histologic finding of androgenetic alopecia. Minoxidil has been used for treatment of androgenetic alopecia and alopecia areata. Two randomized trials suggest that the effects of minoxidil in preventing or treating chemotherapy-induced alopecia are at best very limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 48 patients with varying solid tumors receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -containing regimens, topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      (2 percent solution applied twice daily) did not prevent the development of severe alopecia compared to placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second trial in 22 women receiving chemotherapy after surgery for breast cancer also found that treatment with topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      did not prevent alopecia, but it did shorten the time to maximal regrowth and the time from maximal hair loss to first regrowth and lengthened the time to maximal hair loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     AS101",
"    </span>",
"    &nbsp;&mdash;&nbsp;AS101 (ammonium trichloro (dioxoethlyene-O,O'-) tellurate) is a synthetic compound that acts as an immunomodulator and has minimal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/46\">",
"     46",
"    </a>",
"    ]. It stimulates both mouse and human lymphocytes to proliferate and secrete a variety of cytokines in vitro and in vivo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protective effect of this compound on hair loss was incidentally observed in a study investigating whether AS101 could prevent chemotherapy-induced neutropenia and thrombocytopenia. In 44 patients with advanced non-small cell lung cancer who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    with or without AS101, the group receiving AS101 had a significantly lower incidence of severe alopecia (17 versus 62 percent) despite receiving more drugs (100 percent of planned doses versus 20 percent for the chemotherapy only group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/48\">",
"     48",
"    </a>",
"    ]. The only adverse side effects noted with AS101 were garlic-like halitosis and post-infusional-fevers.",
"   </p>",
"   <p>",
"    The mechanism by which AS101 prevents alopecia may be related to its ability to stimulate IL-1 production. In rats, IL-1 has been shown to prevent hair loss due to concurrent chemotherapy. In humans, there is a negative correlation between the levels of IL-1 and the degree of alopecia (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Interleukin-1'",
"    </a>",
"    below). In addition, IL-1 receptor antagonists abrogate the protective effects of IL-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations with AS101 have not been confirmed in additional trials, and this agent is not commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Alpha tocopherol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha tocopherol was initially reported to reduce the incidence of alopecia in a study of patients given high doses of alpha tocopherol (1600 international units daily) for cardioprotection during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/50\">",
"     50",
"    </a>",
"    ]. Subsequently, two prospective studies were unable to replicate this observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In one trial of 25 female patients with breast cancer, there was no difference in significant alopecia between controls and a study group that received alpha tocopherol (1600 international units daily for seven days prior to therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/51\">",
"     51",
"    </a>",
"    ]. In the second report, 18 of 20 women with solid tumors receiving various doxorubicin-containing regimens developed significant alopecia despite seven days of pretreatment with high-dose alpha tocopherol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Inhibitors of cyclin-dependent kinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of cyclin-dependent kinase 2 (CDK2), a regulator of cell cycle progression, may reduce the sensitivity of the hair follicle epithelium to cell-cycle active cytotoxic agents. In one preclinical report, topical application of small molecule inhibitors of CDK2 reduced chemotherapy-related hair loss in rats by 33 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Inhibitors of p53",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mice deficient for p53 do not develop chemotherapy-induced alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/54\">",
"     54",
"    </a>",
"    ]. The mechanism for protection is thought to be inhibition of hair follicle apoptosis, due to down-regulation of Fas and increased expression of Bcl-2. This observation suggests that local pharmacologic inhibition of p53 might be useful to prevent chemotherapy-associated hair loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Imuvert",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imuvert is a biological response modifier produced by the bacterium Serratia marcescens. It consists of a membrane vesicle-ribosome preparation derived from a series of lytic and centrifugal steps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. It was initially developed to perform immunomodulating or immunorestorative properties for malignancies where immune system dysfunction had occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In animal experimental models, imuvert has been found to induce the cytokines IL-1, TNF, Interferon alpha, IL-6, GM-CSF, and PDGF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. In rats, imuvert protected against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -induced but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -induced alopecia. However, imuvert did protect against cyclophosphamide plus cytarabine (ARA-C) induced alopecia when N-acetylcysteine was added either parentally or topically in liposomal preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/55\">",
"     55",
"    </a>",
"    ]. There are no published human data to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Biologic response modifiers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several studies evaluating the efficacy of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in preventing hair loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/57\">",
"     57",
"    </a>",
"    ]. Systemically administered EGF protected rats from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -induced alopecia, while topical application of EGF prevented alopecia at the site of administration only. Injectable FGF prevented hair loss at the local injection site. The biological mechanism of this action is unclear, as EGF receptor inhibition with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    has been associated with both alopecia and trichomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Topical cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected immunophilin ligands such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A (CsA) and FK 506 are not only potent immunosuppressants but also modulate hair growth. In murine models, topical application of CsA and FK 506 induced hair growth and inhibited",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -induced hair loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/37\">",
"     37",
"    </a>",
"    ]. In another in vivo model, topical CsA protected rat models from site-specific alopecia when coadministered with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , cyclophosphamide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of this benefit is unknown. Drugs that act at the hair bulb are assumed to protect the hair follicle keratinocytes against the effects of chemotherapy, possibly through the expression of p-glycoprotein.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    has been studied topically in rat models and found to inhibit p-glycoprotein and a hypotrichotic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/59\">",
"     59",
"    </a>",
"    ]. Cyclosporine also increases IL-1 receptor expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/60\">",
"     60",
"    </a>",
"    ], which may further enhance its ability to prevent alopecia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Interleukin-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-1 (IL-1) mediates a variety of activities involved in host defense and disease processes. Mononuclear phagocytes, keratinocytes, glial cells, and endothelial cells are all known to produce IL-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/2\">",
"     2",
"    </a>",
"    ]. Dermal and epidermal cells possess IL-1 receptors and are capable of secreting the cytokines thought to play a role in inflammation in the skin.",
"   </p>",
"   <p>",
"    Administration of IL-1 protects against the alopecia related to chemotherapy and radiation therapy in animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. In one study, 48 rats were randomly assigned into four groups that received either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , with or without IL-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/63\">",
"     63",
"    </a>",
"    ]. The rats treated with cytarabine, a cell-cycle specific agent, were protected against significant alopecia by the addition of IL-1. However, the rats who received non cell-cycle specific chemotherapeutic agents were not protected. These results led to the hypothesis that cell-cycle specific and cell-cycle nonspecific agents induce alopecia via different mechanisms.",
"   </p>",
"   <p>",
"    IL-1 appears to function at the level of the hair follicle to protect against alopecia. However, evidence is lacking as to whether IL-1 directly or indirectly stimulates the cytokines involved in hair follicle growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Topical calcitriol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment with topical calcitriol (1,25(OH)2D3, the most active metabolite of vitamin D) protects rats from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    -, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -induced alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/64\">",
"     64",
"    </a>",
"    ]. Effects may be mediated by direct biological activity or modulation of other factors. Specific receptors for calcitriol are present in rat, murine, and human skin cells, and calcitriol induces differentiation of murine epidermal keratinocytes. When human cultured keratinocytes are incubated with calcitriol, there is a dose- and time-dependent stimulation of differentiation and inhibition of DNA synthesis.",
"   </p>",
"   <p>",
"    One study found that pretreatment with calcitriol did not alter the cytotoxic effects of the chemotherapy but did prevent significant alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/65\">",
"     65",
"    </a>",
"    ]. However, other data suggest that calcitriol can inhibit growth",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    induce differentiation of some cancer cell lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44232/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. These concerns regarding the potential for calcitriol to protect cancer cells in addition to hair follicles from the effects of chemotherapy have limited enthusiasm for this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       \"Patient information: Hair loss from cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hair loss is a transient but often psychologically devastating consequence of cancer chemotherapy. A wide range of chemotherapy agents can affect the growing cells of the hair follicle. The frequency and severity of alopecia varies depending upon the specific chemotherapy agent or combination regimen administered, the dosage of drugs, and the treatment schedule. The majority of chemotherapy-induced alopecia is reversible once therapy is discontinued, with the possible exception of the epidermal growth factor receptor (EGFR) inhibitors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Effects of chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients who will receive chemotherapy that may result in alopecia should be informed of the likely side effect of hair loss. Options such as head wraps, hats, or wigs should be discussed in advance so that the patient can be more physically and emotionally prepared. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Effects of chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although scalp protection through cooling or tourniquet has been reported to minimize delivery of chemotherapeutic agents to the scalp thereby potentially decreasing the risk of hair loss, case reports of cutaneous metastases or spread in these settings prevent general recommendation for their use. Because chemotherapy-associated hair loss is transient and usually (although not always) completely reversible after cessation of therapy, adequate counseling and psychological support before and during therapy should take precedence over the use of such devices. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Decreased drug delivery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H217665997\">",
"       'Reversibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Currently there are no available pharmacologic interventions that have been shown to decrease the risk of chemotherapy-induced alopecia. Although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      has not shown efficacy in preventing chemotherapy-induced alopecia, the use of minoxidil during the period of regrowth may help to minimize hair follicle miniaturization in patients at risk for androgenetic alopecia. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pharmacologic interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/1\">",
"      Dorr VJ. A practitioner's guide to cancer-related alopecia. Semin Oncol 1998; 25:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/2\">",
"      Hussein AM. Chemotherapy-induced alopecia: new developments. South Med J 1993; 86:489.",
"     </a>",
"    </li>",
"    <li>",
"     Bruning N. Hair, skin, and nail effects. In: Coping with chemotherapy, Dial Press, Garden City, NY 1985. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/4\">",
"      Cline BW. Prevention of chemotherapy-induced alopecia: a review of the literature. Cancer Nurs 1984; 7:221.",
"     </a>",
"    </li>",
"    <li>",
"     Elder D, Elenitsas R, Johnson BL, Murphy GF. Lever's Histopathology of the Skin, 9th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2004. p.1229.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/6\">",
"      Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med 1999; 341:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/7\">",
"      Liu Y, Lyle S, Yang Z, Cotsarelis G. Keratin 15 promoter targets putative epithelial stem cells in the hair follicle bulge. J Invest Dermatol 2003; 121:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/8\">",
"      Cotsarelis G, Millar SE. Towards a molecular understanding of hair loss and its treatment. Trends Mol Med 2001; 7:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/9\">",
"      Sato N, Leopold PL, Crystal RG. Effect of adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth in mice with chemotherapy-induced alopecia. J Natl Cancer Inst 2001; 93:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/10\">",
"      Wu CY, Chen GS, Lan CC. Erosive pustular dermatosis of the scalp after gefitinib and radiotherapy for brain metastases secondary to lung cancer. Clin Exp Dermatol 2008; 33:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/11\">",
"      Donovan JC, Ghazarian DM, Shaw JC. Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib. Arch Dermatol 2008; 144:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/12\">",
"      Murillas R, Larcher F, Conti CJ, et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14:5216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/13\">",
"      Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/14\">",
"      Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/15\">",
"      Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/16\">",
"      Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/17\">",
"      Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/18\">",
"      Machado M, Moreb JS, Khan SA. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/19\">",
"      Palamaras I, Misciali C, Vincenzi C, et al. Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol 2011; 64:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/20\">",
"      Ljungman P, Hassan M, B&eacute;k&aacute;ssy AN, et al. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant 1995; 15:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/21\">",
"      Vowels M, Chan LL, Giri N, et al. Factors affecting hair regrowth after bone marrow transplantation. Bone Marrow Transplant 1993; 12:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/22\">",
"      Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 2010; 63:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/23\">",
"      Prevezas C, Matard B, Pinquier L, Reygagne P. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 2009; 160:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/24\">",
"      Kluger N, Jacot W, Frouin E, et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 2012; 23:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/25\">",
"      de Jonge ME, Math&ocirc;t RA, Dalesio O, et al. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant 2002; 30:593.",
"     </a>",
"    </li>",
"    <li>",
"     National Canceer Institute Common Terminology Criteria for Adverse Events 9CTCAE), v4.03 available online at file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/27\">",
"      Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer 1984; 54:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/28\">",
"      Vendelbo Johansen L. Scalp hypothermia in the prevention of chemotherapy-induced alopecia. Acta Radiol Oncol 1985; 24:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/29\">",
"      Tollenaar RA, Liefers GJ, Repelaer van Driel OJ, van de Velde CJ. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. Eur J Cancer 1994; 30A:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/30\">",
"      Symonds RP, McCormick CV, Maxted KJ. Adriamycin alopecia prevented by cold air scalp cooling. Am J Clin Oncol 1986; 9:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/31\">",
"      Tierney A, Taylor J, Closs SJ, et al. Hair loss due to cytotoxic chemotherapy: A prospective descriptive study. Br J Cancer 1990; 62:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/32\">",
"      Lemenager M, Genouville C, Bessa EH, Bonneterre J. Docetaxel-induced alopecia can be prevented. Lancet 1995; 346:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/33\">",
"      Lemenager M, Lecomte S, Bonneterre ME, et al. Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer 1997; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/34\">",
"      Parker R. The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia. Oncol Nurs Forum 1987; 14:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/35\">",
"      Knobf M, Kalm D, Mealia M. Clinical observations of scalp cooling in patients receiving multidrug chemotherapy. Oncol Nurs Forum 1989; 16(suppl):200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/36\">",
"      Middleton J, Franks D, Buchanan RB, et al. Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep 1985; 69:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/37\">",
"      Maurer M, Handjiski B, Paus R. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. Am J Pathol 1997; 150:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/38\">",
"      Giaccone G, Di Giulio F, Morandini MP, Calciati A. Scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer Nurs 1988; 11:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/39\">",
"      Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 2008; 26:5618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/40\">",
"      Katsimbri P, Bamias A, Pavlidis N. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. Eur J Cancer 2000; 36:766.",
"     </a>",
"    </li>",
"    <li>",
"     Spaeth D, Luporsi E, Weber B, et al. Efficacy and safety of cooling helmets (CH) for the prevention of chemotherapy-induced alopecia (CIA): A prospective study of 911 patients (abstract). J Clin Oncol 2008; 26:517s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/42\">",
"      Witman G, Cadman E, Chen M. Misuse of scalp hypothermia. Cancer Treat Rep 1981; 65:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/43\">",
"      Ron IG, Kalmus Y, Kalmus Z, et al. Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Support Care Cancer 1997; 5:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/44\">",
"      Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia. Ann Oncol 1994; 5:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/45\">",
"      Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 1996; 35:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/46\">",
"      Sredni B, Caspi RR, Klein A, et al. A new immunomodulating compound (AS-101) with potential therapeutic application. Nature 1987; 330:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/47\">",
"      Kalechman Y, Albeck M, Oron M, et al. Protective and restorative role of AS101 in combination with chemotherapy. Cancer Res 1991; 51:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/48\">",
"      Sredni B, Albeck M, Tichler T, et al. Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. J Clin Oncol 1995; 13:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/49\">",
"      Sredni B, Xu RH, Albeck M, et al. The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. Int J Cancer 1996; 65:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/50\">",
"      Wood LA. Possible prevention of adriamycin-induced alopecia by tocopherol. N Engl J Med 1985; 312:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/51\">",
"      Martin-Jimenez M, Diaz-Rubio E, Gonzalez Larriba JL, Sangro B. Failure of high-dose tocopherol to prevent alopecia induced by doxorubicin. N Engl J Med 1986; 315:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/52\">",
"      Perez JE, Macchiavelli M, Leone BA, et al. High-dose alpha-tocopherol as a preventive of doxorubicin-induced alopecia. Cancer Treat Rep 1986; 70:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/53\">",
"      Davis ST, Benson BG, Bramson HN, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001; 291:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/54\">",
"      Botchkarev VA, Komarova EA, Siebenhaar F, et al. p53 is essential for chemotherapy-induced hair loss. Cancer Res 2000; 60:5002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/55\">",
"      Jim&eacute;nez JJ, Huang HS, Yunis AA. Treatment with ImuVert/N-acetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia. Cancer Invest 1992; 10:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/56\">",
"      Hussein AM, Jimenez JJ, McCall CA, Yunis AA. Protection from chemotherapy-induced alopecia in a rat model. Science 1990; 249:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/57\">",
"      Jimenez JJ, Yunis AA. Protection from 1-beta-D-arabinofuranosylcytosine-induced alopecia by epidermal growth factor and fibroblast growth factor in the rat model. Cancer Res 1992; 52:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/58\">",
"      Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003; 42:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/59\">",
"      Hussein AM, Stuart A, Peters WP. Protection against chemotherapy-induced alopecia by cyclosporin A in the newborn rat animal model. Dermatology 1995; 190:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/60\">",
"      Degiannis D, Stein S, Czarnecki M, et al. Cyclosporine-induced enhancement of interleukin 1 receptor expression by PHA-stimulated lymphocytes. Transplantation 1990; 50:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/61\">",
"      Jimenez JJ, Wong GH, Yunis AA. Interleukin 1 protects from cytosine arabinoside-induced alopecia in the rat model. FASEB J 1991; 5:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/62\">",
"      Jimenez JJ, Sawaya ME, Yunis AA. Interleukin 1 protects hair follicles from cytarabine (ARA-C)-induced toxicity in vivo and in vitro. FASEB J 1992; 6:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/63\">",
"      Hussein AM. Interleukin 1 protects against 1-beta-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model. Cancer Res 1991; 51:3329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/64\">",
"      Jimenez JJ, Yunis AA. Protection from chemotherapy-induced alopecia by 1,25-dihydroxyvitamin D3. Cancer Res 1992; 52:5123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/65\">",
"      Jimenez JJ, Alvarez E, Bustamante CD, Yunis AA. Pretreatment with 1,25(OH)2D3 protects from Cytoxan-induced alopecia without protecting the leukemic cells from Cytoxan. Am J Med Sci 1995; 310:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44232/abstract/66\">",
"      Reichel H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989; 320:980.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1156 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-201.248.109.99-21C92B2D4B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44232=[""].join("\n");
var outline_f43_12_44232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS OF CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23126237\">",
"      Effects of molecularly-targeted agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H217665997\">",
"      Reversibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Quantitation of alopecia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVENTION OF ALOPECIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Decreased drug delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Scalp tourniquet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Scalp hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Topical minoxidil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - AS101",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Alpha tocopherol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Inhibitors of cyclin-dependent kinase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Inhibitors of p53",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Imuvert",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Biologic response modifiers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Topical cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Interleukin-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Topical calcitriol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/1156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1156|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/38/31332\" title=\"figure 1\">",
"      Hair follicle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/1156|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/57/30620\" title=\"table 1\">",
"      Alopecia combination chemo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=related_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13846?source=related_link\">",
"      Nonscarring hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_12_44233="Clinical features and therapy of membranous lupus nephritis";
var content_f43_12_44233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and therapy of membranous lupus nephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/12/44233/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/12/44233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of lupus nephritis (LN) varies with the classification of the morphological findings present on renal biopsy. Ten to 20 percent of patients with LN have pure membranous (class V) LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], though some reports suggest a higher percentage among African American populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/4\">",
"     4",
"    </a>",
"    ]. Treatment is often indicated for patients with membranous LN, especially those with a severe (symptomatic) nephrotic syndrome, an elevated or rising serum creatinine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concomitant focal or diffuse proliferative changes on renal biopsy.",
"   </p>",
"   <p>",
"    The clinical features and treatment of membranous LN will be reviewed here. The various types of LN, the treatment of focal and diffuse proliferative LN, and management of the patient with end-stage renal disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=see_link\">",
"     \"End-stage renal disease due to lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranous lupus nephritis (LN) is present in 10 to 20 percent of patients with LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Affected patients typically present with proteinuria (mean or median 3.3 to 5.4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in different series), hypoalbuminemia (mean or median 2.5 to 3.0",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    peripheral and possibly periorbital edema, and a normal or only slightly elevated serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Microscopic hematuria and hypertension also may be seen.",
"   </p>",
"   <p>",
"    The presence of significant hematuria and cellular casts with or without an elevated serum creatinine suggests concurrent proliferative disease, which is not uncommon and is associated with a much worse prognosis. In a review of 79 patients with membranous LN, 36 had pure membranous lesions, 15 had endocapillary proliferation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis in less than 50 percent of glomeruli, and 28 had endocapillary proliferation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis in more than 50 percent of glomeruli. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Prognosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Membranous lupus nephritis is the one form of LN that may present with few or no other clinical or serologic manifestations of SLE (eg, complement levels may be normal and anti-double-stranded DNA antibodies, which are highly specific for SLE, may not be detectable) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/6,8,11-13\">",
"     6,8,11-13",
"    </a>",
"    ]. In a randomized trial of 42 patients with membranous LN described below, low C3, low C4, and anti-double-stranded DNA antibodies were present in 3, 3, and 9 patients, respectively (7, 7, and 21 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In such patients, underlying lupus may be suspected from the renal biopsy findings and, during follow-up, the development of extrarenal or serologic manifestations of systemic lupus erythematosus. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathology'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsy in patients with membranous lupus nephritis (LN) reveals the findings very similar to that of idiopathic membranous nephropathy. These include diffuse thickening of the glomerular basement membrane (GBM) throughout all glomeruli on light microscopy, a diffuse granular pattern of IgG and C3 staining along the GBM on immunofluorescence microscopy, and subepithelial electron dense deposits on the outer aspect of the GBM on electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef57841 graphicRef74698 graphicRef55226 \" href=\"mobipreview.htm?41/34/42538\">",
"     picture 1A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, several pathologic findings that, if present, strongly suggest underlying lupus rather than idiopathic membranous nephropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concurrent electron-dense subendothelial or prominent mesangial deposits by electron microscopy as in the proliferative forms of lupus nephritis.",
"     </li>",
"     <li>",
"      Tubuloreticular structures in the endothelial cells on electron microscopy (",
"      <a class=\"graphic graphic_picture graphicRef69348 \" href=\"mobipreview.htm?38/39/39543\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Immune deposits along the tubular basement membranes and in the small blood vessels.",
"     </li>",
"     <li>",
"      Prominent C1q deposition in the glomerular deposits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned in the preceding section, membranous LN can be frequently associated with concurrent focal or diffuse proliferative LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/9\">",
"     9",
"    </a>",
"    ]. Such patients have a much worse renal prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported renal survival rates are variable among patients with membranous lupus nephritis (LN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/6,9,10,15-18\">",
"     6,9,10,15-18",
"    </a>",
"    ]. One reason is that many studies included patients who also had proliferative lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/16\">",
"     16",
"    </a>",
"    ]. Such patients are more likely to develop end-stage renal disease compared to those with pure membranous LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/9,17,18\">",
"     9,17,18",
"    </a>",
"    ]. Other contributing factors to variable outcomes include differences in patient populations and in immunosuppressive therapies that may be used for extrarenal indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of concurrent proliferative LN was demonstrated in a retrospective study that compared five and ten year survival of patients with different histology on renal biopsy: 36 patients with pure membranous LN; 15 with combined membranous and focal (&lt;50 percent of glomeruli) proliferative lesions; and 28 with combined membranous and diffuse (&ge;50 percent of glomeruli) proliferative lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/9\">",
"     9",
"    </a>",
"    ]. The mean rate of loss of renal function (estimated from",
"    <span class=\"nowrap\">",
"     1/serum",
"    </span>",
"    creatinine) was significantly lower in the pure membranous LN group (-4.5 versus -18.5 and -15.9",
"    <span class=\"nowrap\">",
"     dL/mg",
"    </span>",
"    per year). The better outcomes with pure membranous LN occurred even though such patients were much less likely to be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Studies of patients with pure membranous LN have suggested a ten year renal survival of 72 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/9,10,12\">",
"     9,10,12",
"    </a>",
"    ]. In the above study, the percentage of patients with end-stage renal disease at five years was significantly higher in those who had concurrent diffuse proliferative lesions compared to those with pure membranous LN (43 versus 14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with membranous LN may have proliferative lesions at presentation or develop them over time, often in association with worsening renal function or a substantial change in the activity of the urinary sediment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. In one series, 29 patients who were initially diagnosed with membranous LN with little or no mesangial proliferation underwent a second biopsy at a mean follow-up of 6.9 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/10\">",
"     10",
"    </a>",
"    ]. The probability of a transition from membranous to combined membranous and proliferative LN at was 35 percent at ten years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NONIMMUNOSUPPRESSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with membranous LN are candidates for more general therapies for nephrotic syndrome, such as angiotensin inhibition, lipid-lowering, and, in selected patients, anticoagulation. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=see_link\">",
"     \"Overview of the management of chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) is recommended in virtually all patients with proteinuric chronic kidney disease, since such therapy may significantly reduce the rate of disease progression, acting at least in part by lowering the intraglomerular pressure. The recommended optimal goal for protein excretion in proteinuric chronic kidney diseases is less than 1000",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    If this goal cannot be achieved, we suggest a minimum reduction in protein excretion of at least 50 to 60 percent from the baseline level",
"    <strong>",
"     plus",
"    </strong>",
"    protein excretion less than 3.5",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several small uncontrolled, retrospective studies that have evaluated the use of ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs in conjunction with immunosuppressive therapy in patients with membranous LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. However, the relative contributions of immunosuppressive therapy, angiotensin inhibition, and blood pressure reduction to any fall in protein excretion cannot usually be determined.",
"   </p>",
"   <p>",
"    Other small observational studies evaluated the efficacy of angiotensin inhibition in patients with idiopathic membranous nephropathy. The results are conflicting and suggest that the antiproteinuric response to angiotensin inhibition may be less in membranous nephropathy than in other glomerular diseases. There are no reliable data on the efficacy of angiotensin inhibition on disease progression in MN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Angiotensin inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although direct evidence for the effectiveness of angiotensin inhibition from randomized prospective trials is lacking in patients with membranous LN (and idiopathic membranous nephropathy as well), many clinicians regard angiotensin inhibition as an integral part of routine nonimmunosuppressive therapy of membranous LN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12607632\">",
"    <span class=\"h2\">",
"     Goal blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal blood pressure in patients with any form of proteinuric chronic kidney disease is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg, or perhaps lower. Attainment of this goal can slow the progression of proteinuric chronic kidney disease. It may also provide cardiovascular protection, since chronic kidney disease is associated with a marked increase in cardiovascular risk. The data supporting these recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link&amp;anchor=H13#H13\">",
"     \"Chronic kidney disease and coronary heart disease\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lipid-lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia, with often dramatic elevations in the serum cholesterol concentration, is commonly present in patients with nephrotic syndrome. Although control of serum LDL cholesterol is the main indication for statin therapy, there is some evidence in patients with chronic kidney disease that it may also slow the progression of the underlying renal disease. These issues, including the goal serum cholesterol, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link&amp;anchor=H11#H11\">",
"     \"Lipid abnormalities in nephrotic syndrome\", section on 'Statins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link&amp;anchor=H7#H7\">",
"     \"Statins and chronic kidney disease\", section on 'Statins and kidney function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome of any cause is associated with a hypercoagulable state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with lupus nephritis (LN), particularly those with membranous LN, are at increased risk for thrombotic events, such as deep vein thrombosis (DVT), renal vein thrombosis (RVT), and pulmonary embolism (PE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/10,15,23\">",
"     10,15,23",
"    </a>",
"    ]. This was best shown in a study of 66 patients with membranous LN, 15 of whom (23 percent) had a thrombotic event during a mean of 6.9 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/10\">",
"     10",
"    </a>",
"    ]. Events included DVT in seven patients, RVT in four, PE without a proven DVT in four, and an inferior vena caval thrombosis in two.",
"   </p>",
"   <p>",
"    A separate question is the possible role of prophylactic anticoagulation in patients at highest risk (eg, massive proteinuria and a serum albumin concentration below 2.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [20",
"    <span class=\"nowrap\">",
"     g/L]).",
"    </span>",
"    The use of anticoagulation for both treatment and prevention of thromboembolism in patients with nephrotic syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR AND CHOICE OF IMMUNOSUPPRESSIVE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy is usually initiated in patients with membranous LN who have one or more of the following (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Prognosis'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent severe and symptomatic nephrotic syndrome",
"     </li>",
"     <li>",
"      Increased or rising serum creatinine",
"     </li>",
"     <li>",
"      Mixed membranous and proliferative lesions on biopsy which may be present at diagnosis or develop later",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The timing of immunosuppressive therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H3874156\">",
"     'Timing of immunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients without these findings generally have a good renal prognosis and do not require immunosuppressive therapy for the renal disease, although it may be required for extrarenal manifestations. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Prognosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with protein excretion &gt;3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    that persists despite the use of angiotensin inhibitors and rigorous blood pressure control should be treated with immunosuppressive agents. Nephrotic syndrome causes significant morbidity, including an increased risk for thromboembolism, hyperlipidemia, and the potential for accelerated atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, higher levels of protein excretion have been associated with both a lower likelihood of attained remission with immunosuppressive therapy and a higher rate of progressive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. As an example, in a study of 42 patients with membranous LN who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    with or without other immunosuppressive agents, protein excretion greater than 5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    was independently associated with a decreased probability of remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, most nephrologists would not use immunosuppressive therapy in patients with nonnephrotic proteinuria (less than 3.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    either at baseline or after therapy with an ACE inhibitor or angiotensin II receptor blocker (ARB). Although there is no direct evidence to support this approach in patients with membranous LN, there is evidence in patients with idiopathic membranous nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Low risk for progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Increased serum creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with membranous LN have a normal or only slightly elevated serum creatinine at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, serum creatinine alone may not be sufficient in several settings. As an example, women often have a lower baseline serum creatinine than men due to the smaller mass. A woman with membranous LN and a baseline serum creatinine of 0.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (53",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may present with a serum creatinine of 0.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (71",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Such a change represents the loss of one-third of her glomerular filtration rate but the serum creatinine is still well within the normal range of the laboratory.",
"   </p>",
"   <p>",
"    Thus, it may be important to establish the baseline serum creatinine (eg, from records from outpatient visits or previous hospitalizations). In addition, estimation equations provide a more sensitive estimate of glomerular filtration rate than the serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A limitation to both serum creatinine and estimation equations is that they may overestimate the glomerular filtration rate because tubular creatinine secretion is increased in patients with nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As a result, a modest decrease in glomerular filtration rate compared to a baseline value when the patient was not nephrotic may not be detected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20665137#H20665137\">",
"     \"Assessment of kidney function\", section on 'Limitations of using creatinine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Concurrent proliferative LN",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, some patients with membranous LN also have focal or diffuse proliferative glomerulonephritis. These patients have a worse prognosis, with a more rapid loss of renal function and higher rate of end-stage renal disease. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of immunosuppressive therapy in membranous LN has not been widely studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8,26-29\">",
"     8,26-29",
"    </a>",
"    ]. The best data come from a small randomized trial conducted by the National Institutes of Health (NIH) that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    based regimens in patients with pure membranous LN (ie, not associated with concurrent proliferative disease) and from subset analyses in two randomized trials of the patients with pure membranous LN who were treated with cyclophosphamide or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil-based regimens.",
"   </p>",
"   <p>",
"    Patients who also have diffuse or moderate to severe focal proliferative LN are treated according to the proliferative lesion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     NIH trial of cyclophosphamide versus cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NIH trial included 42 patients with pure membranous LN; patients with concurrent proliferative LN or other renal diseases were excluded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8\">",
"     8",
"    </a>",
"    ]. The median protein excretion was 5.4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (range 2.7 to 15.4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and the median estimated glomerular filtration rate was 83",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2.",
"   </p>",
"   <p>",
"    The patients were randomly assigned to one of three treatment regimens for a total of one year:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternate day",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone at a dose of 40",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      for eight weeks and then tapered to 10",
"      <span class=\"nowrap\">",
"       mg/m2)",
"      </span>",
"     </li>",
"     <li>",
"      Alternate day",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus pulse intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      every other month (0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      to achieve a nadir leukocyte",
"      <span class=\"nowrap\">",
"       &ge;1500/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Alternate day",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (initiated at 200",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      [approximately 5",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      per day given in two equal doses at 12 hour intervals; the dose was reduced by 25 percent if the serum creatinine increased by 33 to 49 percent or by greater than 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      on two or more determinations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sixteen patients, distributed among the three groups were treated with angiotensin inhibition begun at least one month before baseline testing.",
"   </p>",
"   <p>",
"    Complete remission was defined as protein excretion less than 0.3",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    and partial remission was defined as protein excretion less than 2.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with more than a 50 percent reduction in proteinuria. Both angiotensin inhibition and lipid-lowering agents were offered to patients who had persistent or relapsing protein excretion &gt;3",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    If protein excretion remained above 3",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    the patients were offered treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    if they were initially treated with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ; and with intravenous cyclophosphamide (every two months for the first year and then quarterly) if they were initially treated with cyclosporine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone. After one year, second-line therapy was discontinued in patients who failed to improve and was gradually tapered in patients who had a reduction in protein excretion and stable renal function.",
"   </p>",
"   <p>",
"    The following findings were noted (",
"    <a class=\"graphic graphic_figure graphicRef53268 \" href=\"mobipreview.htm?29/16/29966\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one year, the remission rate was significantly higher with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      alone (83 and 60 versus 27 percent). Among the remissions with cyclosporine and cyclophosphamide, 12 of 19 were complete and 7 of 19 were partial. The probability of remission was lower in patients with protein excretion above 5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      Patients who had a remission of proteinuria were followed for up to 10 years. Relapse after cessation of therapy was significantly later and less frequent with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (20 percent within 50 months versus 60 percent within 36 months with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ). All of the cyclophosphamide relapses occurred four years or more after cessation of therapy. A lower rate of relapse with cyclophosphamide compared to cyclosporine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      has also been noted in patients with idiopathic membranous nephropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H27#H27\">",
"       \"Treatment of idiopathic membranous nephropathy\", section on 'Relapsing disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The data on the treatment of nonresponders to initial therapy and those who relapsed after an initial response are discussed below. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Nonresponders and relapsing disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have directly examined the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) among patients with pure membranous LN. Post-hoc analyses of collected data from large randomized trials of patients with LN have generated the hypothesis that MMF might be as effective as intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in inducing remission, which is similar to the findings in proliferative LN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial (ALMS) compared MMF with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in 370 patients with LN, including 60 with pure membranous LN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/26\">",
"       26",
"      </a>",
"      ]. The primary outcome was a prespecified reduction in the urine protein-to-creatinine ratio to less than 3 or by at least 50 percent. Secondary outcomes included stabilization or improvement of the serum creatinine, reduction of protein excretion to less than 0.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      and attainment of inactive urinary sediment. At 24 weeks, there was no difference in the two groups in the percentage of patients with pure membranous LN who achieved either the primary or secondary outcome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link&amp;anchor=H18#H18\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A second randomized trial compared MMF with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in a randomized controlled trial of 140 patients with lupus nephritis, 27 of whom had membranous LN [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/27\">",
"       27",
"      </a>",
"      ]. Complete and partial remission were attained by 7 of 14 patients treated with MMF, and 4 of 13 treated with cyclophosphamide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A pooled analysis of patients from these two trials included 84 patients: 33 patients on MMF and 32 patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    completed 24 weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/30\">",
"     30",
"    </a>",
"    ]. Among these patients, there was no between-group difference in the percent reduction in protein excretion, nor in the rate of partial remission (defined as urine protein &lt; 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    plus a 50 percent reduction from baseline values) or the percent reduction in protein excretion among 40 patients with nephrotic range proteinuria (&gt;3.5",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"    There was no difference between groups in drug safety and tolerance.",
"   </p>",
"   <p>",
"    Both trials were of limited duration and longer term follow-up has not been reported. Thus, the current role of MMF in the treatment of patients with pure membranous LN is not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Chlorambucil versus methylprednisolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ponticelli group retrospectively analyzed the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    alone (eight patients) and of methylprednisolone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    alternated every other month for six months (11 patients) in membranous LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/28\">",
"     28",
"    </a>",
"    ]. Both groups included two patients with focal proliferative lesions. The patients treated with intermittent methylprednisolone and chlorambucil had a higher rate of complete or partial remission (90 versus 38 percent) and a lower rate of renal flares (10 versus 88 percent). These findings are similar to those noted in the NIH randomized in the preceding section.",
"   </p>",
"   <p>",
"    Among patients with idiopathic membranous nephropathy, most nephrologists have substituted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    in the Ponticelli regimen to reduce toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link\">",
"     \"Treatment of idiopathic membranous nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with membranous lupus nephritis (LN) should be treated with the general antihypertensive, antiproteinuric, and lipid-lowering measures noted above. The decision to use anticoagulation to prevent thromboembolic events in patients with severe nephrotic syndrome is individualized and discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion assumes that the patient has pure membranous LN with the nephrotic syndrome. We generally do",
"    <strong>",
"     not",
"    </strong>",
"    initiate immunosuppressive therapy for pure membranous LN if protein excretion is less than 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with or without angiotensin inhibition in the absence of an extrarenal indication. Patients with coexisting diffuse or severe focal proliferative LN are treated according to the proliferative lesion. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Nonimmunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition, renal biopsy may reveal concurrent lesions of thrombotic microangiopathy secondary to the antiphospholipid syndrome, which may be more common in membranous than other types of LN and requires additional therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=see_link&amp;anchor=H4#H4\">",
"     \"Antiphospholipid syndrome and the kidney\", section on 'Renal disease in APS associated with SLE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3874156\">",
"    <span class=\"h2\">",
"     Timing of immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of immunosuppressive therapy in patients with membranous LN is variable. In general:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe, symptomatic nephrotic syndrome (usually with a serum albumin &lt;2.5",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      are treated concurrently with immunosuppressive therapy and angiotensin inhibition and rigorous blood pressure control.",
"     </li>",
"     <li>",
"      Patients with no or mild to moderate manifestations of nephrotic syndrome and a serum albumin above 2.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      can be safely treated with maximum angiotensin inhibition for three to six months. If protein excretion remains persistently below 3.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      we continue angiotensin inhibition and monitor the patient every three to six months without initiating immunosuppressive therapy.",
"     </li>",
"     <li>",
"      Patients with persistent protein excretion above 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      despite angiotensin inhibition are at risk for progressive disease and for extrarenal morbidity such as thrombotic and cardiovascular events. Among such patients, we continue angiotensin inhibition and initiate immunosuppressive therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only randomized trial limited to patients with pure lupus MN, the National Institutes of Health (NIH) trial, showed equivalent efficacy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    plus glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8\">",
"     8",
"    </a>",
"    ]. There were trends with cyclosporine toward higher rates of both remission (83 versus 60 percent at one year) and of relapse after the cessation of therapy (60 percent within 36 months versus 20 percent within 50 months). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'NIH trial of cyclophosphamide versus cyclosporine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Equivalent benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    based regimens was noted in the ALMS trial subset analysis of 60 patients with pure membranous LN [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/26\">",
"     26",
"    </a>",
"    ]. A limitation to this observation is that the follow-up was only 24 weeks. As a result, most experts do",
"    <strong>",
"     not",
"    </strong>",
"    yet consider mycophenolate mofetil as an alternative first-line agent for pure membranous LN.",
"   </p>",
"   <p>",
"    Thus, when immunosuppressive therapy is used in patients with pure lupus MN, we prefer a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based regimen rather than a regimen based upon",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. Although our approach is broadly consistent with recommendations made by the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/31\">",
"     31",
"    </a>",
"    ], it contrasts with recommendations made by the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association",
"    <span class=\"nowrap\">",
"     (EULAR/ERA-EDTA),",
"    </span>",
"    which suggest mycophenolate mofetil as first-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the NIH trial data, the choice between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    based regimens depends upon a variety of factors, including patient preference. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient who wants to minimize the risk of relapse might choose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      as might an older patient with hypertension who wants to avoid the vascular side effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women of child-bearing age may want to avoid",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      because of its fertility risk. In addition, both cyclophosphamide and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil are associated with positive evidence of risk of congenital malformations. As a result, women of childbearing age should have a pregnancy test prior to the initiation of these drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link&amp;anchor=H9#H9\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Female gonadal toxicity'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=see_link\">",
"       \"Pregnancy in women with underlying renal disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimens are those used in the NIH trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8\">",
"     8",
"    </a>",
"    ]. Both regimens included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day for eight weeks and then gradually tapered by 5",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    to 10",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      is initiated at 200",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      (approximately 5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      per day given in two equal doses. The cyclosporine dose is reduced by 25 percent if the serum creatinine increased by 33 to 49 percent or by greater than 0.3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (27",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      on two or more determinations. Therapy was continued for one year.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      can be considered an alternative to cyclosporin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (0.5 to 1.0",
"      <span class=\"nowrap\">",
"       g/m2)",
"      </span>",
"      is given every other month for one year (ie, six doses). If the absolute neutrophil count is less than",
"      <span class=\"nowrap\">",
"       1500/microL,",
"      </span>",
"      the dose at the next infusion should be reduced by 0.25",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      body surface area or even transiently withheld if the counts are very low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preferred",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    regimen is that used in the ALMS trial. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Mycophenolate mofetil'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nonresponders and relapsing disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the NIH trial, patients were considered to be nonresponders if protein excretion was more than 2.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with less than a 50 percent reduction from baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Initial cyclosporine or prednisone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ten patients either failed to respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    alone (n = 4) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (n = 1) or relapsed after cyclosporine (n = 5). Relapses occurred during tapering or after cessation of cyclosporine therapy.",
"   </p>",
"   <p>",
"    Remission was induced with the above intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    plus glucocorticoids regimen in eight. The probability of remission (mostly partial) was 70 percent at 18 months and 80 percent at 36 months. None of the patients had a doubling of serum creatinine at long-term follow-up.",
"   </p>",
"   <p>",
"    Another possible option, which was not used in the NIH trial but has been effective in patients with idiopathic membranous nephropathy, is repeat treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Relapsing disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Initial cyclophosphamide therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    group, the data on suboptimal responses were too limited to be helpful. There was one nonresponder and one who relapsed following remission. One of these patients achieved a partial remission following treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and the other did not respond. Five additional patients who did not attain remission with cyclophosphamide therapy were not offered cyclosporine: three had developed subnephrotic proteinuria; one had declining renal function; and one had leukocytoclastic vasculitis that was treated with daily oral cyclophosphamide.",
"   </p>",
"   <p>",
"    When choosing the criteria for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    therapy in \"nonresponders\" to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , we prefer the cutoff of subnephrotic proteinuria (less than 3.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    to that of the criterion of the NIH trial: protein excretion &le;2.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with at least a 50 percent reduction from baseline.",
"   </p>",
"   <p>",
"    Another possible option, which was not used in the NIH trial but has been effective in patients with idiopathic membranous nephropathy, is repeat treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of idiopathic membranous nephropathy\", section on 'Relapsing disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The apparent benefits of cytotoxic therapy in this setting must be weighed against the adverse effects of a second course, as treatment-related complications (primarily bone marrow depression and infection) are common, occurring in as many as two-thirds of high-risk patients treated with daily oral cytotoxic therapy. In addition, the risk of gonadal toxicity is high in patients who receive more than one course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . We almost never give a second course of cyclophosphamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Combined membranous and diffuse proliferative LN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with combined diffuse proliferative and membranous lupus nephritis (LN) have a worse prognosis than those with diffuse proliferative disease alone, which has raised the possibility that such patients may benefit from more intensive therapy. These observations led to a clinical trial of 40 such patients showing significantly better outcomes with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    compared to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ; all patients were treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/12/44233/abstract/33\">",
"     33",
"    </a>",
"    ]. Twenty-six of the 40 patients had previously been treated with cyclophosphamide or MMF. As a result, we have elected to present the data in the topic on resistant or relapsing disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link&amp;anchor=H15#H15\">",
"     \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\", section on 'Diffuse proliferative plus membranous LN'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=see_link\">",
"       \"Patient information: Lupus and kidney disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pure membranous (type V) LN is seen in 10 to 20 percent of patients with lupus nephritis (LN) . Patients with membranous LN usually have proteinuria and signs of nephrotic syndrome and a normal or near normal serum creatinine. Other clinical or serologic manifestations of SLE are often not detectable at presentation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with membranous LN are at risk for progressive disease. Patients who have or develop concurrent proliferative disease have a worse renal prognosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nonimmunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonimmunosuppressive therapy is given to almost all patients with pure membranous LN, including those who require treatment with immunosuppressive drugs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend angiotensin inhibition with an ACE inhibitor or an ARB (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The proteinuria goal is less than 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or, if this cannot be achieved, a minimum reduction in protein excretion of at least 50 to 60 percent from the baseline level",
"      <strong>",
"       plus",
"      </strong>",
"      protein excretion less than 3.5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Angiotensin inhibition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal blood pressure is less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg. The supportive data are presented separately. (See",
"      <a class=\"local\" href=\"#H12607632\">",
"       'Goal blood pressure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The management of dyslipidemia and hypercoagulability in patients with the nephrotic syndrome are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"       \"Lipid abnormalities in nephrotic syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=see_link\">",
"       \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive treatment for the renal disease is indicated for some patients with membranous LN, including those with nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rising creatinine, or membranous lesions that are associated with focal or diffuse proliferative changes. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with pure membranous LN who do NOT show a decline in proteinuria to less than 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      with angiotensin inhibition and rigorous control of blood pressure, or who have a rising serum creatinine, we recommend the initiation of immunosuppressive therapy rather than continued observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Initial regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;If immunosuppressive therapy is administered to patients with pure membranous LN, we recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and either intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    rather than other therapies (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). The choice between cyclophosphamide or cyclosporine depends primarily upon clinician and patient preference (eg, less toxicity but higher relapse rate with cyclosporine), after a thorough discussion of the potential benefits and risks. We prefer the cyclosporine- and cyclophosphamide-based regimens used in the NIH trial. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Relapsing or resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the NIH trial, relapse of proteinuria occurred in 20 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and 60 percent of those treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . The choice of therapy varies with the initial regimen that was used and with concerns about toxicity. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Nonresponders and relapsing disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We prefer the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based regimens used in the NIH trial. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'NIH trial of cyclophosphamide versus cyclosporine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who do not respond to initial therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among patients who respond to but relapse after initial treatment",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , either intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or a repeat course of cyclosporine may be used. Patient preference may help make the decision, particularly in patients who did not tolerate the initial regimen.",
"     </li>",
"     <li>",
"      Among the infrequent patients who do not respond to or relapse after initial intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We almost never give a second course of intravenous cyclophosphamide.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/1\">",
"      Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1992; 19:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/2\">",
"      Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/3\">",
"      Neumann K, Wallace DJ, Azen C, et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995; 25:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/4\">",
"      Bhinder S, Singh A, Majithia V. Membranous (class V) renal disease in systemic lupus erythematosus may be more common than previously reported: results of a 6-year retrospective analysis. Am J Med Sci 2010; 339:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/5\">",
"      Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/6\">",
"      Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 1977; 56:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/7\">",
"      Appel GB, Silva FG, Pirani CL, et al. Renal involvement in systemic lupud erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine (Baltimore) 1978; 57:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/8\">",
"      Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/9\">",
"      Sloan RP, Schwartz MM, Korbet SM, Borok RZ. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996; 7:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/10\">",
"      Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/11\">",
"      Adu D, Williams DG, Taube D, et al. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. Q J Med 1983; 52:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/12\">",
"      Sun HO, Hu WX, Xie HL, et al. Long-term outcome of Chinese patients with membranous lupus nephropathy. Lupus 2008; 17:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/13\">",
"      Beck LH Jr, Salant DJ. Treatment of membranous lupus nephritis: where are we now? J Am Soc Nephrol 2009; 20:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/14\">",
"      Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/15\">",
"      Pasquali S, Banfi G, Zucchelli A, et al. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993; 39:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/16\">",
"      Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006; 70:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/17\">",
"      Adler SG, Johnson K, Louie JS, et al. Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classifications. Mod Pathol 1990; 3:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/18\">",
"      Schwartz MM, Kawala K, Roberts JL, et al. Clinical and pathological features of membranous glomerulonephritis of systemic lupus erythematosus. Am J Nephrol 1984; 4:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/19\">",
"      Kanda H, Kubo K, Tateishi S, et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005; 14:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/20\">",
"      Karim MY, Pisoni CN, Ferro L, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005; 44:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/21\">",
"      Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004; 66:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/22\">",
"      Kasitanon N, Petri M, Haas M, et al. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus 2008; 17:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/23\">",
"      Mok CC, Tong KH, To CH, et al. Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study. Medicine (Baltimore) 2007; 86:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/24\">",
"      Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005; 20:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/25\">",
"      Myers BD, Chagnac A, Golbetz H, et al. Extent of glomerular injury in active and resolving lupus nephritis: a theoretical analysis. Am J Physiol 1991; 260:F717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/26\">",
"      Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/27\">",
"      Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/28\">",
"      Moroni G, Maccario M, Banfi G, et al. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998; 31:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/29\">",
"      Mok CC, Ying KY, Lau CS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004; 43:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/30\">",
"      Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int 2010; 77:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/31\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/32\">",
"      Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/12/44233/abstract/33\">",
"      Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19:2001.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3093 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-61DB87C3C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44233=[""].join("\n");
var outline_f43_12_44233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NONIMMUNOSUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12607632\">",
"      Goal blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lipid-lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS FOR AND CHOICE OF IMMUNOSUPPRESSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Increased serum creatinine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Concurrent proliferative LN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - NIH trial of cyclophosphamide versus cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Chlorambucil versus methylprednisolone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      THERAPEUTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3874156\">",
"      Timing of immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nonresponders and relapsing disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Initial cyclosporine or prednisone therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Initial cyclophosphamide therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Combined membranous and diffuse proliferative LN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nonimmunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Initial regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Relapsing or resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3093\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3093|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/16/29966\" title=\"figure 1\">",
"      Treatment membranous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3093|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/16/16649\" title=\"picture 1A\">",
"      Membranous Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/42/28321\" title=\"picture 1B\">",
"      Membranous IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/46/39656\" title=\"picture 1C\">",
"      Membranous EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/39/39543\" title=\"picture 2\">",
"      SLE Membranous EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=related_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/49/36626?source=related_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=related_link\">",
"      Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/41/37530?source=related_link\">",
"      Treatment of idiopathic membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_12_44234="Malignant gastric ulcer UGI";
var content_f43_12_44234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62708%7EGAST%2F64355%7EGAST%2F62794%7EGAST%2F51673%7EGAST%2F51893%7EGAST%2F63601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62708%7EGAST%2F64355%7EGAST%2F62794%7EGAST%2F51673%7EGAST%2F51893%7EGAST%2F63601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1173px;\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Malignant and benign gastric ulcer as seen on upper gastrointestinal (UGI) series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper GI series showing the differences between a malignant and benign gastric ulcer.",
"    <br/>",
"    (A) Malignant gastric ulcer of the distal lesser curvature. There is the biconvex meniscus sign with a nodular ulcer mound (arrow).",
"    <br/>",
"    (B) Benign gastric ulcer of the lesser curvature. The ulcer crater has smooth margins and projects beyond the gastric wall (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy, III, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFKAR4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDwLoaWkA5pe9BQveiiigLhRRRQIKXFABzU4t38kOFOCcUDIMU4DNOETEgBT+VaVjpryNuZQB70BcpxxjaCcA46etPdVJUBQfwrbi0oFcZBPTpUX2BFJMjE88ADFAirbWCTAYh259yf606/0w2zKyu2CBj61t2H7qIBYhyeuM03V23xKeB3oFc5WYnneOagbrWhfR7HYY/SqRQnJA6UDIxSmlIpMUDE7UU4D6UtACYoxSgUoFADcUEU8ClVGeURopeRuAqjJP0AoAiIpCK6vSvAHirVJNttoN+q4z5k8LRL+bAZrstL+BPiK5Tdd3ljagnAA3SH8elArnkWKMV7sv7Ps20bvEgDdwLHI/8ARlZWpfAnXLe8jSz1G0ubRvvytG0bJz/cyc/nQFzx3FJXofin4UeIdDiaaNFv4FGT9nRt+M4+7ivP2UjIwQe4NAxhFJTsUh5oAKSlNFACUUtFADB1pwpo606gAooooEFFFLQBNbBfNAcZXvXQw6fvtTFnByfmHrXPouGzhvbg12+lxgworMTuGOR+FAM5j7MyO27txzWnaCVTGGUYJ596t3VsBOw4x9Ku29qNq8E4piJraI43BRmqlxatvYAc5zmtyCEMuFB6dahltiWAGRx1oEYtpbs1yAOTVnV7Jo4kYjKkYHHfFatjbIJNxwCOO1aV5aCbTWXGWQ5HT0oA84vYWOcr2q54W8OXXiC5u4LVNxjgaRunGCMd/erepwBS/QNXd/BoQabbX17MfMec+WVBGAooGec6x4RvrGFT5e6VSd6gjkeo5/SuXI7d6+lvEsOkX9sTFP5b8n5CCRz0I9K8G120Wy1ObzkilgLsAyOA2M9eO/1oaBMwRRinOF3tsztycZ64oFIoAOat6dY3Oo3sNpZQPPczNtjjTqxxmoFXmvqL4AeB7bTPDcGtahYgardkyI8qjfHERhQvcZHP40CbOQ8D/Ameb7PeeLLjy1zlrCEAk8cbpA35gDt1r23SfCGi6Vg6dpGn2zf3orZFbH1AzXRpEoUYFP2Dk0CKYt8dsY54oEB5zj2xVxlxjCk59McfnS7R6UAUDBlsio2gBFaLKPSmFFA5/pQBkXFosiFWUEEc15D8SvhRZ6vF9q0aOKz1FRn5ECpL7MBjn3r3CRRis67RSvIFMD4Sv7O4sLqS1vYWguYjh426g4qvXv8A8fPDEU+mJq1nB/pdu4EpUD5o8HOfpxXgJpFJjaTFKaSkAUUUGmAwdadSLS0CCiigUDFqSLG4bhxTBUiDPWgDotNtTPErPn5TjrXV2ETNFEvbtzjHNZ3hq2Etom8gg+hrqIYTkEYAHc8UyWZDWLF92D1z7CrYhAUZz9BV9l2kdz+lDKzc8LTERwqqADaeatLb4UNzg+hpot1Lj58+tXGWOGMKWPzCgBkVuvBUHH1rVtYFCEEg7ucAg1kDnG1jitKxUqOGxxQBzmt6YPOYYI5J69qy7O+bSlkhkLiI5YbMZU+tdNrE7JMd33RXEeIblELYIzzgbuppAQa54guIZsW04dWzu456+orl727e5kDln3nO7JzmkupDKxYkZPNVjkmkUkHU1ZsbOe8uYre2jaWaVlSNF6sxOAB+PFSWNlJcXEUKRtJNK4REXqzE4AHvmvqr4O/DeLwnafb70+Zq1zGu8HG2Addq8deeT7fmA2c38K/gythJZ6x4nZ/7QiYSxWkbjZGccbzjLMM9iAMd692jTgAUsa4AxUqggdc0CGgUuKcOmKXFADCPTikI5NSY5pMduBQBERxTCv61M3HemsPpQBXZB681RlRWBIYEZI4ORkda02Bx15qpcDPfnFAHIeIrGO7tZYZV3K64P5V8cavp02mXstrOOYnKZ+nb619q6zhYWz2r5M+KqLH431ArIGaUIzgfwnaBj8gDTBHHHrRTnGGI4z7U2kUJR9KWkoAavWnU1OtPoAQdqUCgCn7eKAECntWnYWolOSuRVFIyQD26VtaQgUkAAnrigTOt0hyqqo6AZ4rpLY+Yh3AhR+dZnhe2EhJYAHHbrXSRwCNslPlJqiSjOEGNobdjqRUKAs2TurVurdH+6SNoFMSCMKep/wAKAK0aBGyBnPr60+VfMC4Qgjg89auJDGcghuMHNaFvaRttxGTxxnpQBz6K2Pu/pWnbRkxknJzTnh2XW0wsq4Jzjj6VdhXci7hhQOn4UAYOrIdzH5lVVJPPtXl/ieYSTDHTnH5V6r4sO20cx5ORjPtXkWuqfMBbOTSY0YjZzVm0h3/vD0HQepqAIWkAFaUC+WI9wIXpSGe0fs76dZ3Gr39zcxI11bpF5G7OVyX3EfkBX0ZCowBivkX4e+KJfDGsx3kcZlhPySxbsblz/MV9PeEvFWleJrZn0y43SIqmWJgQ8ZPY56/UcUxHRDqPpTgM4oHTpxThSEHbpSY9qdRtx04pgNPJoxS0GgBhBHpSYODn1p9NbjrSGREZqtcjjvVpuneqN5JtXjNAHP604SMnNfJHxRaF/G2oGDPITzDnjdtHT8MV7d8cvE11pGh7dPm8m4mlWINk5AIJOPfjvXzRK7O7PIzO7HLMxJJPqTTBDGOVAxyM856j0/n+dNNKaSpKCkoooQCJTgKSPqam2UwGoOKlVARycU2FflB6irMYwMEAigAVflwCc9a09NQ+ZwT07CqiplOcD8K0NPjIkbj8MfSgR23hicx7uDkZ4ruQVuLZc8Nz0HvXA6KTC3zcEnHIrqrOUhyM5BXiqJLUqnzTknbgY469KRVBJ2/yqOZ8QnJGcenvRaTIq4agC5FEN3RiMAEgVrWK7GUDkDByRWcZWkjxjA46DmtWwwqFm5wMdKAKrbS7s/LEn8aiJxkAEDsKszqodioweMD2qruI5x2x0oAyvEEPnabJgZKfMRXkevxgP3yK9ouF8yKVCOGUjpXmXiPT3WdwYztH8QXjpQwRyVpbE73YECtAxnykBB9sVfhgwgVRgfSnvECOcY7UrDM+3Bi6kjJr0L4X+IJ9F8QWrRGAJcyxQSvKD8kZcbsHPH/1q8/kXAI9KksZ2ik56buRQB9yRnKjBqReleH/AA2+KUdvaRaf4idEtoY1jguI4ySABjD469ByB9a9c03XtK1CBZbPULWVCMgrIM/l1oEatBqGC4guAfJljlxwdjBv5VMcetAAKTHPWilPBxQA00xsc0srKqlnYADnJ4Arkdb8feG9GaYX2r24ZMAogLkHnuM0gOnkdVHJxXnvxY8Yt4T8P/b4YPtDGVY9hJHXPeuE8efG2GK3CaDCJhLGGjeQFSffHp/hXi2qeM9S1h1XVfIlgLKXVYsnA7DJP+elMZT8WeJL7xLqbXd/IwX/AJZwhiVQf4+9YZqe8EAmP2V2aM9Ny4I4qvSKEooopAFIKXvSUwHW65Yirnl8AjHaq1mMs/pgVoKo2Z56cUCIoE/drgdRVlYz1OMfSp7OLdEhwMlRxVtYkXPAP1oAqQxNjG0kVradFmbJA9enWoEdehwMjjFWbVxuYZxkUCNqNssAeSetdTpyMxR+oIODXI2cyKVG8nnHSu5sWX7HGOMjnjFUhDZ4HMcbKuc5FNtoGMmX7HBFaFnhyYyCTnIpJMLIzEY56DFAGlZquPug8D8604I2JORhTxisGO4LACJCo4yevFa0MTsMu+FxnOQcUAWDbqfvAkj2qnsWNdrLzipLiUPF5YcjnqB1FUGRQSwkPtxQBZkQMWwu0j071yOvWY8xsqSQPTOK6cFcncxxjjisjVwGGc9R6UAcbd2gXaVA9CKzpUYZBFb15GzbRtHGenesydRuyfxpAYs0XOKrJFtkYHj0rUnTBPHGeKzywEm70oGWbZznaDgnnirqyMqhhwazYflOc81ZifPO4Z6UAatneywyJJGxR1III4I+le6+GfElz4s0qVLScWuv2qtJFtPySYA4IJ6Gvn2N1JGOv1ra0PV5NL1GG6hcpJEwYEdaBH0IviTVodK86/tLeC6XIkBVgqt/30eK8y0b4r+I7vx5Ppmo/Y4bNA6qsMRXkMNpJZjn0/GvSPG7xzaf50MqxuzFMNjB6dfXHp714P4/itbexuNZ0twuphgjgbTtIYZI/L8qAKnxp8VeIdR1GOC5vJY7Ek4t4ztRyCMEgHmuW1vN74et7yJPKLJmRR3IYqR9OM1s63c23iLwtbT2wX7Uqt5inBZHyM/mAfzri7PVGtILi1mQyQSHG0n7vY4/z1FA0ZbMdoGBxTSc/WjHyn2pvakUJ2o7UUUgCikJo9aACjtSd6KYE9kMl/wrUhJEWSQOOtZ+nvtWX0IH9aubv3Tcgcd6BFy3ZljiwcjaOfwp6yFVOSarQPiFVyOACalUlvu9aBFqPnnBFXEIBx1NV7dG/iI5q7sCcgDP1pgXbJQGGegrqtPuwsMeGII6/nXGrOw/OtvTn8xEAZQevJoEdrYuZeUbbgMfrxTWuIhGwOXb17VUtJ/KtSCSTs7HHcVVLbnYBiAT36daYGgl4VddpwvGQK2Irzfb9wBgCuaRlDAFsgelatpIgUgk/hQBaaXH/wCuoGmYD6VMXiII5Ue9Z9zIidie/WgCd52x1qtNIGX5j271C9wpPc/jUcjCQH5gB35oAz9QYQRMVzg9x61zlxIVKndnPY1t604EMSg/eyT71iTRB1U5BHJ69KAKcsofOSST+tZUx3MwY9eBith4QARWc1vls+vORSGQRzAjbn5gOasJKOCM+n1qsYyrc/8A1qsRjco7H07g0AWonJ5OeferNoTLcqmSSxCgDvVPO04B/CtDSSFv4JOm2RSfzFAHt3jm8NroVlHI2J3aRz6EnGf6V5LrYyZLdXDRXSMVGRyykH/GvTPiTvn06xeJeDDIwY9FO1R/SvG9WaSPUtNcybgsoSQE8Jnjj60xGF4PcR69NZuxEcqsm3I5YH/DNS+I9KisobkbTuXDK341Bolvv8cpFuAC3Ehye4Ga63xBGLsXcLYx5ZHB9qQzzODltmAS3AzTFXMm08UkTFXRl6gg1I2ZJXkOBk54pFEJpDQeaTtQAp9s0etHeigAo60lLQBZscbZM/7P9asOD5bHH4ZqtYnG/j0/rVmbmB+eo9aBFm2wFUY6VbiKg8KSR0H4VQgbGOvQEVfgY5DY/I96ALkDTGQErEseOcMS2fyxV9mARsdetUoh8uSa0Ybd5FyVIB6YzTEVmDSPjaSfatazjkVo1CkYPPNW7PT1AQhgfU5q3CgWfGMc9fTmgRs2iZsUzy/RiTzVO5Pk/wCsIHH9at2b4cxgnDcVm66WXy0AO7HQDrzTAfBKGcDOc9OtalqTnAz1ziuf0pZWcBQcZ6nNbsJ8uVSz8dcigC7JnIUH71JcRAxKf4xnOOmKcWUyBgSMf4UjsQoORuAz6cYoAyJFKMeevegjcc+o6VburYSrvj+VumM1XCMhy4x9M0AZGtx4SE+mR+orMQ4j+b+db+qRb4QMEsvIGfzrm7ncpwfwpANldScY6+tRSoMdM+lUzKSx+vFToxKnPNAyDgNu5B9c8iq5k2429BRdOVA2g1VXcerEY7UAWHu93yg8+ma2tAOb+1jZC5aVRgd+RXLyYXBBP1rpfAVxHJ4r0rzRuUTqe/YGgD2XxvORp9haQkyMEb5txGfmAORXhvie+cXUdpGhDJMuAD1IavUPGF39l06yu0T5jcNk57ZB/wAa8v1uO2/4Se1kRt3mSiQpk4BLUMEUvDYRfFN3Lc5LQrK45/i3Bf8A2atu31CL7fJBK25pPlAOawdHlRPF96Zx8rvMCM4/jz/SrFzbTRay1wvKA5UelAHK2cTS3UMI+V2cIM9jnvV3VkNrdSw5B78VDqTsmqzyABG8zf8ALxg9c0B/tUybULyuOSSTk0hlMj5c+9JTpcb2C5wD3ptAxKKKKBBRRRQBNaHG7Pt/WrMhzAc5PFU4D96pnbERH0oGWFfaB64q3DKAi9Tzms4HGKt2aF2BONufzoEb2n/PhjnGeldDGQsXfNc7aPtCjj2rYik+Q8DimSa9pL8rDtj9asLvEo2jIzzWVBeLGSCOvp0q/HcAgDkg/pTA1bEySTxhEJcsAMZ65q7q9opdT950PPHfNJouIJFlPzd/pUt1cLLchVAwefpQBkRiQHhSpOCBjFTRg8EscioZ7wIxyBgHrUZvN2NinJ/CgDTEuGxnj2+lSo+8cEk49Ko26PIAQvrzVq1BQjLEn0oAmuEaOIZ4Oe/Gf85qpluep55qzcSyuAoRcAHFZ7GTOSx6dCKAEu+g3DNc5rSAKrKCOvAHSti7diG+U/hWPfNuTlTg98dKAOfc4fjPWrBfC9f/AK1VrjIlzjJBx0pQ+eCBkAfhSGV7gnbyT7ZqJSNwyR9adKQcjIzmoFdQwzg0gG3A+Y4JOe9bPgZgnirTCeQJxj64rAnYnpyPepdNmkhuopoh+8icOo6cg5oGer/EWYR+F7Nhk/6XIDj6LXEeL4YrXxBpawoiqsmDtByTuHJr0L4u6aY/CkVzAwFvHqCN0xhZFBH+FcN4ygWTWdLIUkmXnA68g0xI5DWY2i8T3aoxUtOSGB/vH/69dPao8tlJNMWKt8o47Dis/wCIFiLPxPA4GEmVH/HPNdjpVusujZCjaGPGOOtAM8u1qHydQZQxYEBsmrth5VlppvSN0/IQEdM8Va8ewLDq8OxQFNupOPXc1UNPt5JrEoI926QY/I0hmT9fxpSOO+atalb+RePEONoGc+4zVZ0KgFuM8igY3FAGTWlY6TNdWklyuFhjBZmPQAdTWa+3cdmSvYkYNACd+OlFFFAhY+M1Ix+Wok707oKBko5/Crlu+1AFxVJT2qRGx0oA3rWUDbnHPNafn4QAcjtXLpN3BOauR3DFfmb8KCTaNwM/QZ4q5aXqhkJPGefeuq+GXhO21S7uY9at5i4iLImQAOnJ/Ouyu/hPolvaz3LLfbB8yosy5Jz7r0pgcDpWpNcSbY0MhB4UDNb/ANluY1WWWF0DcglcZ5rqPB3hGxtYrmeK3mO7ICysD39gDipbvTryzfzYZmSEP8ycFQPcUxHl81tKXy/yr69c1YtXhXAwW+tbHjDV7YSDesLKR0MKZI9N3WsG2s4Ztstg7EbQWRyMg9ePUUAb0dxttmKKMgcDIqpHdvjldufWqBlYZBkA/EVVjALuAVO31IoA3mvOCNwyM96RLhSG34OOoIrFuY3RlZD9eRTPOkDYIOO5FFwNaZ4TglF9iKyL9QwPAAyRmnu524BwD0yao3cvygAg4BoAwdTbYzEEEf8A16pifIyAPWn6y4GB/EazUkGOT2qSiaSUmqrydulOY+/NV5D83HSgB5bI4NIrHJGaizSg896Bn0auzxB8I4Ipo1lE8DR5C5IlRQY+/quM15xNK91eaGkK75TLh8jturovhJqgk+HPiixuWCpaIbmNjgbD8vf8ay7K3WPx+00EYEboJETjC7vmHtx0pknOfEf/AEjxZaxAgE7E47ZIrs/DFqE0eWNSCQ2R6HmuA8SlpvHUcZGX+0oD+LA16FYyR6Rpkl1fN5cMal2Przxj68DHqaEDPMfGcp/4SCXfhtqgAdgOcVr+CLEiwkuJgG3viNT6Ac/n/SuPnln1K/aRhuuLiThRxyTwBXoUdrcWVnY6fCqI3lB5T1JfGCPpQhs891Cc3F7NKTuy5wfUU+ysZbt2JzHbxjdLKRwgxn8T6Cu5sfCum2FmL7WJcRxYLg7cfTB7k9q4nV9Ra/nYhRHb7iyRKoUDjHQd8UguWNd1gX6pbWcIt9Pi5SMDBY4HLc4PfFY9LSUDsFFFFAgTvTjTV706gYoPNOzxTKM0ASB61NBUS3rM5ASKJpWJ6DaP8cVkZp6O6I6qxAcbWweo64/z6UAeo+BPF+qpqyPDcQQWbSeXh9pJUYO3p+tfVdqEu7YDAKMAfpXwjolwbfUYX3hQrZGema+qvhf43XVrYpdLHChwYnMvL5OCCMcY/WmS9DvLuBbWM7AMHsPwrjfGuoCx8N3SEgzzAEAemf8AIqx8TfF8GheHLm4hnQzKQo2MCRlgCP1r5u1T4halq10ZLpsJkKq5HC5+lArCahJPfXDSyuI41weSBmpNMv5rZleNtpToQM1zGqahPLKYidsa/LtHfB4p+kzus53NmLGG568cc0Dsdot2t3LwVSc8nJADH29KlgixMFb7zBsjvwK5WK923I8vgg8NnPauzhzdW9veEjfjYeeuB/higQ4QNcwOqsFcLkZ/CsZ3lifbu5rat5fKDBTgkYqjcoJ2k2k7hzyaAK5nd/vHt69KgkYng9/SrMMYYY7/AFoe35AzkHPegDi9VlMl1IeODj8KoKxrSv7cpM/ORms5uvXpSKHAk8VG2ehpVODwaDlu9AEdb3h3wrq+vDfp9tmLn9452rxjP+elP0bTbaC0j1PVeYi37mAnHmY/iPt6D2r0TxN4vuNI0b7DYtG1zcg72VhhOBz05+lMGyGHT4/CmiXOhpewXeo6jk3MltIDHFGNpCg45JPf2rV8LRW8ut3E3/PK3wSTx8rYH86xPDVv5NncX9/MZpZEyd5Azx/9auw0S0ji8LXWpjhpRgDpxkGgk820OxXWvipcZ4WGR5ceu0gf1rb+NlwLC1ttNiOGuVWRx6qpOP1H6UvwUga48X61qBGYyDGG92fcf0FYXxlvhqvjqSOPPlWgFoO43Akn9T+lA+pH8ONDheFtZucF438uBCeN394jFddGu/U4mgcvcOMbsjoM9P1qS0hWysrWzhKJHbxCM7j96TuR9a5HTPEU4tNVvPkgktI/IgfPDMdw49+/40C3KvxE1XeE0qMhlSQTO4OecHA/XNcIamuJ5Z5Wlmcs7HLE1EeR0pFoZSmj60UAFFFFACDpS0i9KUUALRRRSAXFL2puKWmBJGdhVwRuB6Ht713ek+NV0zRYxBEwukXbGNx5YEfMTj3z+lcGEJBYA46E46UnpQK1y/qGr6hqLyteXk8okYuyGQlc5z0zVEUUDrQM1ZLJjLEGIaSRA/Xp9asrAbVAZkwSOAKboqTXl/GZJPlJAO4ngV0V1DbtCh8t32k4eRiox7Cgk5/TzvucyYIHv7V3djdBdKQE4QTfKP8AgIrmrC3U3AIjGByABxXQWsVzd7I7O3eVQM/u0J570wY6biYqTkD360iW8nmSNjCMp45rUGmTgkzmCJsZwzgn9K1oYLJLaRJAJGAOCWxnI9qYjk0R88UPCWweQTXSROC7RiIIg4A9KkUFW2mAXCn+6Mn8aLAebavasJXKqSG+YVzEqYcivXNW0+2vJ3W1kSGYf8snDKQfTkYrgNa0K8tZGdkQjPY8/rSY0c6F54q3pqW5vYBeE/ZjIokx1255pyWj7cnap64ZsVPp2mXN7exW0MLs8jYGAaQzqNUjmvvGwj+zuttbY29dmFXjHtWbeQPf61PHyULBQwHHQZru9Us3spLiSWRGcW8VuNuSTII1Vsn/AHgao+HdFea6BjKMcYJJPLH0pklHXpZLY6bYRLkztg4J6cV6v4ptP7N8DGAZUxxhcdyWIJrm7bwjdXnxMNreLELfTYgXk3NsYttOFOOTXs00Nnqlx/ZwsGmtww82VgdvHvj+VAHnHwn8M/2X4U/tGVCj3BklYHPQEgf+g15dp1ql943upXXeqXPm5992RmvruOxt4rMWqQotuE2CPHGPSuXk+Hvh+Nrmazsfs1zMQzSRyP1Bz0JxQB5ja2EEm6+uIQLWwT7RIvOWYdB+JrwTxDrkmpJFbxwJa2sJysKNkZ9T619IeMNNvvDfgDXndQzOEYNGCcIrA88fWvlaQ7mJIGSc8UMaIyaCeKDSUigIpKU0nSgA70nNLRQAg6GnU1adSAKWk/CrmmWMt/dLBBsVjzuc4AHqaYFSul8LeD9U8RTzR2tvLEkcTSmaSJtmBjjOOuD+Nep+HfA0MSxaTcW0EitGkkVw8YPmTFcncD/Dk49sV6v4O8M3emQSi8igDvwdgByMf54p2JufL2vaBdWNhmzt5ntLdf38hQ8k4+Y1ymME+or7M1rwdG1nNb20MaW85LzcDPSvA/HXhS00rRdSXy4UntHV7eQEb5QXwVJ9NpJx7UAmeXU5RntzRtPJqSNCThTk+o6CkUd54T0oJGJpHRnZQcICQvfk5/lViTSpppY0HzNkK0kz7VXNHw60q/1yWSzs4cWsSI0zBgjMuepJNesf8K8M2rfaJwkWmtZpEoXadkoPUDv9e9Mg4vUvCX9hXFpFNPHeSzp5ixICEUbc/Mc5PrVOee+giM0k5jt/uJEpKoxx2ArptY027NnchnB+xyLCHdAXk+XoMHpXPapbwRxAWwln1edT+7lTgAjBxzgkY4+lMCixZrl0nu4VYDlEYsV6enFaraeuCzSSbe7dB+XXvXMpozrbmWE3QullwxwuGY46c9sGvStKifTtWnbUUF7DdJtitygYgjGWyT+H4UAclqFvd6dc4kO5WG5WXP3fU1YttR+zgFgd3XODmul1ya1W9nZIlB3Yw4zsx/D+FY0kUZkVirIhJ2snQ/rxQBB/alldyf6XCSwxywNa7QaDLpyvGWkY7dy7GIDH69ayysVu0rSvlQNwwBn0rTsdXtJx9kidPNjUfe4yfY59qAMS6iSOaOOPw7FcROMiSXeFP4girkd9DplrkJp+mheskSO7Lx0BZjzTNJTW9cnks306W0g4YXDMMJjOT15zXPa7pMIvImjna980hfKxgBsdznvjNAHW/C23fxPqKaneKq6dBI6RxknMhAHOO/3uvSvXV8I6bB5lzZwiMkEjZnhsdetcx8PvCrwWGnTzIkDrlkWMAKoK4IIB4716lY2ggQoPmX3pAYWgaNENOAlle5mZi8sr8Mzdv0rpbeBIQBGuAKSKNY0YIgUHsO1ToMKBQAhHFIFxz3p2PpQaAKV/Zw3lrLb3MSywSqVdGHDA18efFn4cXfhTXJDpVlez6M0YlEyxs6wnJyhbnpgHJ9a+zJgxibZjdivK/jVoeu+IfDzWemKsasFZ/nC/MCcgnPTFIaPj4+3SkrR1vTjpWovZtPDOyAZaLoD6VnEUFCUGg0fhSASgUtHamAi9KWkXpS0AKOmTXtvgX4ewf2bpN7IS0l5EJXc8FM/MABn6CvExXuHwo1LVJrSB9QvZ2tFfYkSKo4xxTQmfQek2FmlvbEW6b41AVioJHFbIU9aoWaxm2jaNSMgHHer6sCOeopCI7lS0EgQDdtOARxnFfMPxr8PvpkEl7dPJNcXkvlxxomVQ7gxbOfQEfjX1H1Jz0rzz4s+G7nW9LhSyuBBsYtIAqksPQE9KYHx4YZPPWEqVlLBcNxgnpXWeEvDv9s3UUPmAQCRVYonzOCTnJz/jgViXOl3UetS2McbvOjsibsZb5toP6/hXe+Atbm0R7vTfsix6orGLc4HqRgA96Q2epeIPCx0jSxdaTHHA626RGGOPAlAGCWOfStbR549X0C20+OY213bxIzKOQ3Xg8966vwjcS3vh+0OqqDO6BSJAATxXBa7o8/hfU9RudL0ie/tb8ZmaAgy5yeB7UyTTitW0EvcRBprWRQsg27ij44IH9fauA1cWBvH+yyXsd0+5N08YzyvJB3ZFa/h2S6vtLENybm2tIpFa3uPMVeAvKNz2rk/FFjY2Wp3sVrc+bJGRIgkk4HAJwQaYGzpcNrL5Hm3Rl81HUhflBbGBk9//AK9ZNxaXqSyppplQBGiV5yAsecbsc9cd64uTUpntxbCXaiuzAk9jjj9Kkvb1Zdq3U5kbGFYt93gUrgdRbzST3KwSS7liG0ZUfMc/ePNSXEJsJT5k6RMf4QevNebyy3cBkbfhF5G3B7006vOYh+9dmHQNjAouOx6dbW9vcwM8khmPUAnkc9jT1s0jWSaG1UbCB5mBwa4bQrwvBOZpwrBc8MASPauz8KahDHpMttIZHjbDqCBt5zyTTES/2zfajFDHD/qYCCUI5x0z9K6Cy8FTJ9lvNMjLGXY0pzyuByMk+9cFp5uItdmXSBsVlPm5+6WIOME+g5r3bwYJdM8PWmnO++5VQ3zsO/PJoA1vC1h/ZWkW2nwsz3MbiVpCoAJZc4611encSyruJJw2CeF4GcUWduqQo2AGI7dKtxxqjMyjBbrUgPc4U8E0oORmo5Cei8moYpX/AHisOQTg5HI9aYFvOO1Jn14qs8yoEQthmOOlVZNSjiuCjf6vgK2fvMewoA0icVheJbC51O0NvBci1QkFpNoYsMHjrxUr6zauoCzxFw+xgGBw3p9ao63eC4t4jby7ZUJcAdGxkYP+e1AzyvU/h/o2k2bHVLe3uLcy/KRAokdiPb6V4J450W10bWpYtNm82yPKhj80Z7qe5+tfSvxMtNTudFtbvRLvy9QWSN2hKowKgHcAD7183eNrO6j1B7m+eGS5uCZD5QwcY6kDgcCgEcwaVR1opR0pFDKKU9aSkAgp4KbPukvnOS3GPTGM/rTQTtK5O0kEj6Z/xNLTAUcV7n8HLpbax0+znlRXlcyEseikfKK8i8L29nc6zAupzRQ2YOXLvtzxwPzr6M0fw3pF9a2l3ZBhhR5bI4KsMfSmiWeu2zKI1AYY9QfarauCSOK57Q45BbRpKDlfl5PXFdFEgUHk/nSAeBXP+MmMelSMkixyAHaxPHUV0DEAnJ/WuM8eSSSWvlqhePd8xB5Ugjt3oQHgni+2j0u6tb+4PmsrufkIB5xyOOuR+lXbUafcXOn6na35nQL5iuGAYODyG9O34Ve1hrPUo1kiljW5gfZ5ZIyhLDDfQYqGXwmsdrff2c6xmTbJNMGDAkkklBj6iqEemX+uxXnh3S9Ttg/2yErIFRvl3cZDVgaj4g1nUb6BxvtbeUYCk/KcAk849q57RZGgNtcR3MkQt2XMbn/WYxx07+lbXjvxpa3vhK0j0kiS7kbmIHBTA5/WgDltavbvSrC50e3uBCyyb0LpnC4+n+c1h6hFDc6TbXck8Ut+AEIVgRwPvEelc/rPi671HEFwx8tMEgsM7gMelULfWFQbVOO31OKVx2Ibuyudzyhw2SScfX0qhNFcZGQcmultbuLaN7oFHOeParDzxupClSvqMZBoA5620+5ngcFwDtyoz3yOv61Yj0KVRy6Fs88cCrv2tIS2WwuQCM9KJtQlltsWo2gn7x7+tAEa2tvY3EO9l80DeST9eK0Jtdjkiit1zEoGMIc7uw4rGvraaW5Dzy4DKMkcYp1jaq8qFeQuBnPWgDt/DOtw291bK7P5aKzKuARwDx078V6to3jGa8toJJ7BIFYhWkLbiBjjsOvWvH7GFFjDKuNvGT3qRb+WLUQJJznggZ644oEfSGj+IkvLqW3WVP3AGR2bI4APrXQSalBbW7TXskVvGoyXkcAfrXgfhzx1FpHn3AhaVeu0kdvQ4rpbO41bx8j3BiS20y5OxYi2SuNuWzt5FAHVp4/0q81F47KTzVRW2kNgSEY46Vyfxe+I9zoVnY/2NLEk827eQQ44xgdKk1DwzF4ekEixtPYc7mVdpTj19+lVtT8GWPim9tJIZkWOIkrGHyCMjg8cDigDibb4n+L7rQ5JHughGSNsCjK57Hbk/nXNR/E/XINFNhLeNJHJJv4OHTnoGxmvZ4NBuNJvFspXzaMwSIIehJwR0rJ1P4brb3Cy7kuRMShgmwS0ec7c465PWgDJ+Hnika/qYga0aO5MiOZHlBHmYHOMdTt/WvTTDeS6o91bxhYYIFiMWeGYsxZhx7gf/qrye10iP4c6w91M2+LCzpufB3gkKhOOOePxr1iHxAmq+GIbvw9c25vJ0WQwPKFZDjkHPoeKAPOvHNw8umia51FUErnbLGcEx44IH4GvAtW1ee5MtvFcO1oTySMGT3bv+FfROl6bc2PhmYa1qSLM0g2Tyog3hk5RRjjv0weDXz1q2mC109rlpEL/AGx4sKeq7cg/p+tDGjEo980uQehBpppFAeTSH3oooABS0gpaANbw3pseraolrLOsAKkgk43H0r638D6bHpegWEAYNHDEqrjoeOo9q+Q/DwVtas1d9gaTG7GccV9LWHiQWljFYj7yKiIMnJGO9NEs9Mh1FCQqpj/a/CrqzuSGDAg1hPbMumxzA7T5eWyO2MmuX1HxLdWemyzpEwC52Bs8t2z7UCPTPnOWY4A9K8R+L3iG5XWbePTNQj+0RNt+z+aVxn+9irlt48upbW6hu9Yjt7hEMm1YWOAB0zXh/ifxlNq2uz3ckNvgzHbKseH2bu3PUj1oHua3iJJvszTxxzrq982wbJDtBBBZl9u2ffNbvgvxjdNpAs57cmRY/LLNn5+vFUJprq3gGqWOnyalaOkYiZoXLQg/e245B61iPe65I622naelqiIQDEjfOWJI+Ynqc9KAL2svPfxubKdkmjAZowxGwk9iK4M3l0rEi4nXd1AcjpXU6tb3dmGjmP2OSfYXGSMY/wDr1izLZFlFxOrEKMlAck/UcUAjHCk+tW7WxeZgAcD+96VpC10pwphvgHPVJEZT+eMVoW9jJGqrBCkwPeNif60h3MW4jjtwVWXew4IzRb3GWfOckdcnk1tv4deSYmS3nQdSAD+fSpZNAhjfMazqRyc80CuZj3PmxlCv7xcN7+n4daagu5HBXdtX17HNbtvosalysnzYwWYEd6uR6NcuoEEfmZz93OOtMDEeFp7U+YkjFTznr/n/AApIC0Bj2AhSB8o711KeH5Ex9umWAE5Ksdv/AOutTT/C9nMqzWlxHckKAY1JyOfzNAHOWt3PJG3VcdNp6UtvGbqYsQcqcHA5zWhrtk1jaO9tCd/+yCa57wjBq11rsNskUpjlkIZmU4U4J/p0oEeleFtCF00SNCCpOCDnPv0r3mzktLKzghjiEMeNkaDsB6fnWLpGi2mkWFt5SAXRjVWZs+nJx2yc07UtQtLOZZNQl2W6cJwWJY9wByaANnWZ4oYF8xWxLlD3znsfauF13xJZ2Nvc26TLZrGnysgO4NnqMetU/iN4tSzs8R3GEceYjEEYXAzkda8H1vXZNc1KGDSWmaESCSWWQthjn7vrt9vegD6L8MeN9PuLW3guZHuZ2UgSMDmQg8Z967Sza31WGC5EX3Gyo9OtfP8A8MvDNxPdSvcTzIUUvHHECwznouTxXs+i3Mtk/wBisbaSdwR57tnbH7E0AQeP/Cdtr8EatAjMMAlmI2jOQcex5/CuV+H+hR6RqAjuUmM06HaJh8oK53YPocg16zGvmhZGXbxgqe1cv4i+3Lcw2mj2ERKsrmWbITac7gCDkHgfnQBpT6PbX8MQniQtDIHXPQMO/wCprhPiJ4Ls59N2WUKWhzlp41PyDHLE/gK9Rty32ePzAofaNwUkjOOaranYQahb+RdIXjyGwCRkj6UDPjj4i6U8dxEtojzw26yFplViAuFI3HseGrgWGCc19peMfCmmjT9SbTtNX7ffW/kFkBOBgAHHTjFfN/xe8NroOo2ccETybYcS3CoQrEBevYYyaATPOqKU0nakUA6UUgpaAJI3MciujYdSGB9CK9r8CeKrPV77T0ufLSRFxOGU53YP5jNeI1e0i/bTr+G6UZ2Nkgdx3oQmrn2tPqFvPDb2Ucy+dKBhOc7cVzHxP0Oa9XT0t/MW0Rm88oeg+XBP61zHgrXv7V8U2ksEQGIFAJ6Y2fXrXr1yn2uycIAzEco3f2pkng8vhG7udP1Gc2ztc7TAFwRiIj5nx3rzo6RPpGvskQSGGMj9665dh3IBPHI7V9CarpOo6h420XUNIRYLe2ikju4ycZBxg9ee9c74m+HN/qfieHUTNEoRw2wDO9cglev60AUp/FQ8MeErBZ5IrlZ0cmby2DA56FR9QOfeuI0jX4WWXVzFKCjASgMQucnbkD+Vex+IPAKav4aWxjuFtyCXdUTJzySAc9zivBZ7C5sZrnT7ZSkUMhE0UYBLOMgbmPJ/KgDC8UXk+p6zJcXLFnfHXOAPQViH71bWo2V1HM0k5CljuPJOKxsZPAzSKEDEdDWvo0bxyrMVYEcjBwKXT9HkdUmlU7W5ArYgtT8oUYHpgUA2WG1K884GGSQfLnhjVk+JNQjUKyxSDkHzFzx9af8AYmVenO3HT3qhd2LGB+oIHNMRZGuktzaW249xu65+tXrPxVdwuqxNHHj+6v8AjXLCOUAbhn3FAk8uZSo6deKANzUdWa6uWmmw8xOdzEnvWFPqE6yCRHaNl6bCRg+1PnZZGBUemRjpVG6wOD+dAGxZeMNRiTy7zbexYx+9yG/Bh/XNer/DG5tbvVbaxm0+e2vQY7yBy+4SI8YPHGDgV4t4ctlvPEGn28gBR5RuBGQRjPTv0r62+FmjyQeFdOl1SygivowyxEKN6xEnaCevQ0AzavNRhVJvtUbRQJ0eRSFcgdj3rz3W/E+j+VPdNfRKdrYkeCVvLAA+6MV61cWNvcxeXcwxzRZ3bHXIz9K8z8aeDoZLjyNPgSK0nBWVAnCjjp9aEI8S8TavoOqZjGr3LAZzJ9nkw3tg1m6Xq2g6ZA/lSylx02wsS35nAro/iD4STS3eKaFo5ViPlIiKEjXj5ie5J/ICvKryE211LCxBKNjPrQNHofhjXb3VNQlt7G6fS0l+SOVHfzJSWHy5BwOB2+le2fDK31i2vGglEs1vC22WV9wycnoe9fLmjqJPOLGYCBRKGiGWjO4Ddj6kD8a+s/grq11qHhOJLl3maNiBLIuCwJP8v8KAPSVIIH04rL1WVLdopHICgksx7DBOf0rVUcDNZmu6Wmr6Vc2UjeWJ42jZgMkAjHFIDnfh/wCNR4tjmkSxuLeFSfLkeNlDL+PeuwGCM9c15XZwa94c1e10SHVrGO0AUQyzQks6qvTAOAccde2a9PWVREGLAg9+1MBtyqhXY44Wvmf4hyX3inXvEtnCEgTTowUbb98MgyrfXNfS7OJR6Y6ivA/jft0JdWuraJDPqZVMouGyIwpJPoBQB86SoUdlYYZSQR6EGo8U40nekUNHSlpBS0gFpRTe9LTA2/D3iK/0K7hns5D+7yQpxzX0hoPxBsLnwxFcmYrczZwDjIbAyP1r5WFKODkcH1FArH3F4Pnie3eGZt10MsxI5x/k1tXNhHOM5ZWHQqcYNfGtr471tZYWjvzauuN8igfMAfp+lezz/FpNNvreea4S406dAcxlW2557dxTEdj4s8Qz+FGgkvIZLuweQI7xAb0BIAyOM9f0ryj4hG0iv7jUdKmkW3ul855QgAT2Pf8A/XUXi74xWmsb0trOURAgYliRt4zzwentXl2v64dYvIyYzDax8RxKenJJJ9+aAsO1q7V7ZI9zMxO/J/WqFrZyELK6kIeQa1rK1F6kYZAYwABn0z610CacLtorW2Vd2AACQo49STigDG027myY9xKjp+Vdn4Z0PUNVv4rWKBVdhuJkUAAYzW58JPD9jPqs93fwCaG34QOgIL47g9cZr2rTtNtLdhPHGoMp83dgZ5FAjyy+8N29nrttp7B2ViolkAHQjt/k1J4r0G0t53ggshHEPlLHGSMcmvT9TtrZ5Vdo1WbO4NgZ7Vz3iu7t4ZokkCGV853DOBxTA8c1DSIbXzJI428tTgEqDnmsm8gsEWNjbkueWwAMV6H4pNq1mDtZGVucYG45HNc9f2NtPp8E0flqcYySMtzQByD2lrOf3Ucy/lxWTrOmvZIu5t27BxjHHNdjpNorXYMjsFQ7ivHOOn4VZ121t75RtiEjoMYwAf8APNKwHnuipJBqEF0jPHJEwdCvXI7/AEr7J0PxNYy+HbPUJZkVZlUMPRyOR+ea+ULREbUYDBDvg8wBgMZIGSefw6V7R4ZlSycBpLVbCOPcFZUO0kcBs/h+NFhnrKa9YGeKCSdY7iQbliY4YjGc4qfUbq1gtWnuGURoN25ug968c18rqt7Hcm4s0KxCSTBVSMKQACOSCeMA96861m81jRbmaNJVVXXMkQkXJzgjrwcjFFhG58ZdYvZb+7lsYpBA42DzCMY2gM20/SvDpWZpCXOT3Ndx4h8Va5PNLZS3UVwVzb7ZLWIsoI4KttyOPftXFT20tuI/NQqHB2nIOccUmUiXTbt7K6SeL/ddSMhlPUEf56V9g/BjV9L1HwhZrpaFEjypVwNwbc2c/jmvjVa+g/2efFmk2ulHRpyIb8PuBfaPMJYkYPfqBQDPosds0Gs7T9RW7Ljyni2kKN+Pn+lX88DAFAjD8S+GbDxDCkd9G+5G3LJGcMDj1rB8K6BJoF1fWNzdTXNo8oeBpTlgu0YBI9MV3B5FZt5avcXA+ZkUHO4UAXH+VeFHT0rwj4wRy3+najcXSM0lv5sEMKAY+ZB8/wBfr6GvaJmQW7wPMQcY3ZGRnpXlvxFsdORYbWeKOKJpDOG3AZlA+U/zpoR8qmkq1qSBNQulByFlcAjuNxqrSLGjpS0gpaQBS9qSlFMBR2p1NFOoAcKBxnHSgUtADo03uqlgoPc1etdMkuLjy43Vh6iqcUbSSKqjJJr2X4S+CZNWdbh8i2jI3HHLdeF4x25oE2c3p1k1jpu3qxAxmu68E+FW17RL145BHKkiEkclhzkY+p/SvS/Bfgy1tbR2v4vPuDITukQDgdAAansbP+xfEjxxQrDb3IypQnaWGeCMUyR/h7SLfRbC3toycknLyHksRya6WRQLRQMfKvFZOvmLZDPLOqQBvmOQMHHXNSRX8FxCyLMCcblKt1GM5B/woAS4RpmyDnC8VwHixPtV0yysUZASp6YOABVvxT4ke3cm0uZ4GI3MISm4YYdmVhg59PyrnPEetx3lp9tiMyhyylcj5GAHtz6/jTApPcC7s9soBZTjY2ATg1j3ChY5YpptoUn5eDnniqsl3iJizN5wbruBDVmTzSXM+5pW27u2OPfpQBVfVfst48ZVGjhZQzh8Ec9qnuvEv2iFktT5SyAfMMMd3+1XHyzf6beI7MVkkJ6A4O447VBas0TqyyHqCR60rjsddots73yiRoztPAJ7kYH612cGooLGW2NurwF13Mh2knHPP4V5zBrcnnxhPk2nKc9DzjmvYPBHirTL3TU02/skBhXLOCqiU/XHH/1qBF6zhtokhtZrN1t2WNRN1VsgELnr1P51BqfhOGa8lvZZSYsBDEBnAAABHHXivQ3eC4MTTtFHZyhdkbcEHAI5qa6W3JuLzz9iRjYiSOoRgAORxTA8V8S+Frmwmnk8rz4tjSSuvIPtnsf8K4V9NtLu4nW4nEVnG/zIuAV9ME/zr6H1y7trbQ5pkmSS2cux8phgqV5Gcdf614Tq99bXEcVlb2zJBI7Py2WYf7Rx0+lICbRfh1pesX9jFZawGWTLzRMfm2+isBgmsnxv4Jv/AAj4lhgtJHMM6mS0uN2CMZ+UtgfNx+tejfCbw6ia1bXPnu1tNH5Maj/noGDMw46KvH4ivfL2xiuLRrZ4klQjHzqD+PSgZ4D8L/iVfILaHVm+1MFWLzp32sOele96Lq1tqtus1rPHJwMqrAkfXFfLPjLwZrFteyTLbSadGJ9satnYSScENXq3wP0TVdPWefWSUdcBOg3gg5PAGR6UAexBvXrUU8mxCetJI6xplmAX1PSq91+8QqpG6kB5F4t1bU7qXWryyYWDWj/ZnDtu2qOfMxj/AB6V5N47+IEuvafEkrec6zMYQTsZAFUbmA9TyB9a+i9Q0ON5NQN2ymK5Ksw4ycDucc18qfFKytdP8d6pb2QIhUo2OMBiik4/OmCOVldpJHdzlmJYn3NR0rUgpFDR0paQdKWgBaBSUtACjrThSCtzwvop1m4mUbz5Sg7EGS2TQBjjkgAZPtWxa+HdVuADHYXG0jOfLP8AhXtHhP4eWI1JA9lugVSVLg/e45JzXtuk6TZ2sCxxxoSvcCmTc+VNE8MzxE+ZbsCo3NuBDdeuOuK9o+GEsEFtHbvqcsbBtsVtztGSfw5J/Wut8dadajSJrlIVFxCMhlHzEZGR78Vy3hOxjEsN2sBEYIYF8jBycDigR6sWEafMDwBz1zXO65qUUivHZyA3EbDjkEe4/wDrVqeZLLYSPCxdyvy9+a8g8WtqmkavDeuZZoGQBsA8Pg8frQgL+uarc6haS24XEMhHyEHI/vAj61k22p3Fpp9sn70SRblAJOQMcY9gaSwvV1KHz0mMdyD+8UNg5xjdVO81i5achwPlXBJFMDMu9QkednmLliXVj1JBxUusBYdIMU7xrMuXUZ+8uBj8ajv7+1ucM1tEjBcHywQD+tZWpRwzNtSYhscKfpQBjJdq0eNjBwevaqlxI24NGxB9jzUkkDo5+Z8HtVfA385JpDMW8/d3L/LjJzVSNsP6D1rS1mPDJInIxg/nWNvywB6UhlzIVgcnPY+lbk3iAXMNpHI0iKn+tKdTgdvb2rAO5yoUHOKlSzAVSzs3qqr/AFoA9H1fxpZy6Fp0dtqDERIsTxZbIAXBBGPbr71van8QvDV/pyRGaZWtFHk5Z/3ucZDYHTjvXi1zHEjEJGR05Jqrkc+uKdxWO48ReNreSCa00aC4ihfglpyV9eFIH5VzcOrKmowzNE7W6vl4y2S6ZyVz1GQMVk5BJB5q9Z2ksib0gkdevyqSMDrSGfWfwp0uGx0uG/WfzormMfZVXcRHG3O3n36/SvRQeOc18/fB3Wdcgh0e1lgZ9MR5IkzuOwHnpn1PH1r32J/MTdtZTkjBpsRV1O1hu7Z4rhFaJlwQ3TFfOWu/FHW08TSafoUVtZWNqxiVp5CSwUkZ6ZAPoAa+lLqETxNGSQGGDj0rx3xH8II77xbDewXBgs5Im85osiQOSTxzjnj8ulAHoHhnUbjUdFt7mQxSs4BLQklDx7gH9K1obmOSENGSfcCud8N+Fk8PW8arqF7dKH4adySq7QAvXGAR6d66DIiOAyHPGCMUAVtRiM6NwSu0/jxXyz8Z7BNN8WahJKsb/a4VWPa/IIC8kfgK+qNQcLExkYqCO1fM/wAcotEju4xbzStqO5ncbtw5A7mgDyI0hpTSUihopaQUtIApR0pBThTAcK9L+C0c9p4pLTWkpjli25ZCB161wvh6NJtasI5UWSNp0DKwyCM9CK+xoLK1idzFbQIQcArGBxxTQmy7bReQGVIsuOeK0LYkpHJKHjcn7pzViFR85wM56/gKgviQEwSPp9aCTkvFJN3dRrJcPAqyEOgJ+Zfce/8AWqOkW+q2EqxWdobnTZXHzsSSBnqD+fWr3jLh8jgmPn3ro/Bv/Iu2v+6f/QjQBowp5NqhgHT7wP615n8Xbh5ltYoZlWJcO/BJDc/416nIBtbj1rxn4zAJNZlAFJXkjjuaAPPbGSRXOxzuHBArRkbMBdnfc3H1qhpvMi/57VNqjHy1GTjH9KYFaZgMAMCe/UVVeQ+b15qT/lmPwqvcAbQcDPrSAjKsoPPyjsagaJXGclPwNJN3qkPvD60AM1OINbtGgJbtxXPrancpdguf0rp7sAR8DHy9q5s/cNIpF2EqkQwv6daUvjAXAGeT+FVZCdsYzwO1Oh6fjQIpzMWZiSTURyTmlk6U6LlufSgZp6PpYuQZZt3lgOVQA5cqASB+dex/Drw7dFBbyWCKs0LS4ZThBvUhG9CevrgVh/C+NH1/QVdFYee3BGf4BX05bQRRhmjiRWb7xVQCfrTEY3hnwvY6KskttD5dxM3mS/MSM+wPA/CukHTrxTV7/WlXp+NIAPWmMB1yBTz1FM70ARkZ4JFV54VIyeCDkMexqyoyxz6VG/3TTAw9cR4tJn3mWbKnPlg7h9Mc18wfFjQDY3MF0iylnQmQOxLLz3/xr6w1Ti3fHHFfOXxT/wCQdq57qEA9sjmgDxQ9aQe1OamHpSKP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant gastric ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast upper GI study demonstrates a large barium-filled ulcer crater (arrow) surrounded by edematous mucosa. The ulcer is extending from the stomach, across the pylorus and into the duodenum, features that are not seen with benign ulcers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infiltrating gastric carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper GI series showing infiltrating gastric carcinoma in the region of the incisura. There is irregular narrowing affecting both the lesser and greater curvatures (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A double contrast upper GI study demonstrates a gastric cancer infiltrating the wall of the gastric antrum producing an apple core lesion (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonthan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leiomyoma of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 192px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper gastrointestinal study demonstrates a well circumscribed smooth- appearing mass (large arrows) arising from the wall of the proximal lesser curvature of the stomach. A small central ulcer crater filled with barium (small arrow) along with the well- defined margins of the mass are typically seen with leiomyomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leiomyosarcoma of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 218px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast upper gastrointestinal study demonstrates a large irregular polypoid mass arising from the greater curvature of the stomach. Irregular masses arising from this site are typically malignant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Norman Joffe, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal upper GI series",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal air-contrast upper gastrointestinal study showing normal gastric folds and small intestinal anatomy, and no masses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul C Schroy III, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44234=[""].join("\n");
var outline_f43_12_44234=null;
var title_f43_12_44235="Reduce lead absorption PI";
var content_f43_12_44235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ways to reduce the amount of lead your family takes in",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Make sure that your children wash their hands and face before eating and sleeping.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not let your children eat anything other than food (such as dirt or paint).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clean all the surfaces in your home with a detergent. This includes floors, counters, tables, and anything else a child might touch. Cleaning is especially important for toddlers because they crawl and lie on the floor and like to put their hands in their mouths.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If your home was built before 1978, it is very important to remove any flaking or peeling paint in the house. Before 1978, homes were often painted with lead-based paint. Hire or speak with a professional certified in lead paint abatement. Painting or putting wallpaper over lead-based paint are only temporary ways to control the problem and are not acceptable solutions. Anyone who removes lead paint must wear a special breathing mask and other protective gear while they do the work.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give your children a multivitamin with iron every day. They should have well-balanced diets that include fruits, vegetables, grains, protein, and low-fat dairy products.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not use herbal or folk medicines (these may contain lead).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you have pottery with a coating that might contain lead, use it only for decoration, not to hold food or drink.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store food in glass, plastic, or stainless steel containers, not in open cans.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use water from the cold tap for cooking and drinking. Let it run for a few minutes before drinking from it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep materials that might contain lead away from children and areas where children spend time. That includes materials used to make ceramics or stained glass, and those used for other hobbies.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44235=[""].join("\n");
var outline_f43_12_44235=null;
var title_f43_12_44236="Protection 1 to 5 years after stopping VIT";
var content_f43_12_44236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sting provocation test after stopping venom immunotherapy of at least three years duration",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Insect",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Sting challenge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Years since stopping VIT",
"       </td>",
"       <td class=\"subtitle2\">",
"        Number with SAR (percentage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Urbanek",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td rowspan=\"2\">",
"        Honey bee",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1 (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 (14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Golden",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        mostly Vespid",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        mostly Vespid",
"       </td>",
"       <td>",
"        2-5",
"       </td>",
"       <td>",
"        7 (9.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M&uuml;ller",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        Honey bee",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        15 (17)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Haugaard",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        Vespid",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keating",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        mostly Vespid",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2 (4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        van Halteren",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        Vespid",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"       <td>",
"        6 (8)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAR: systemic allergic reaction.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Urbanek, R, Forster, J, Kuhn, W, Ziupa, J. Discontinuation of bee venom immunotherapy in children and adolescents. J Pediatrics 1985; 107:367.",
"       </li>",
"       <li>",
"        Golden, DBK, Kwiterovich, KA, Kagey-Sobotka, A, Valentine, MD, Lichtenstein, LM. Discontinuing venom immunotherapy: Outcome after five years. J Allergy Clin Immunol 1996; 97:579-587.",
"       </li>",
"       <li>",
"        M&uuml;ller, U, Berchtold, E, Helbling, A. Honeybee venom allergy: Results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702.",
"       </li>",
"       <li>",
"        Haugaard, L, N&ouml;rregaard, OF, Dahl, R. In-hospital sting challenge in insect venom-allergic patients after stopping venom immunotherapy. J Allergy Clin Immunol 1991; 87:699.",
"       </li>",
"       <li>",
"        Keating, MU, Kagey-Sobotka, A, Hamilton, RG, Yunginger, JW. Clinical and immunologic follow-up of patients who stop venom immunotherapy. J Allergy Clin Immunol 1991; 88:339.",
"       </li>",
"       <li>",
"        van Halteren, HK, van der Linden, PW, Burgers, JA, Bartelink, AK. Discontinuation of yellow jacket venom immunotherapy: Follow-up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997; 100:767.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44236=[""].join("\n");
var outline_f43_12_44236=null;
var title_f43_12_44237="Vancomycin dose C diff diarrhea";
var content_f43_12_44237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70347&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High and low dose oral vancomycin are equally effective in acute C. difficile colitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 372px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Disappearance of diarrhea was identical in patients with acute clostridium difficile colitis who received either high (500 mg four times daily, red line) or low (125 mg four times daily, blue line) dose oral vancomycin for 10 days.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Fekety, R, Silva, J, Kaufman, C, et al. Am J Med 1989; 86:15.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44237=[""].join("\n");
var outline_f43_12_44237=null;
var title_f43_12_44238="Cryptococcus neoformans in CSF";
var content_f43_12_44238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58455&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcus neoformans in cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of cerebrospinal fluid (x1000) shows likely yeast forms, a few with cell walls and budding. These forms can be confused with host cells on the Gram stain and are more easily identified by India ink. The most definitive procedures are testing for cryptococcal antigen and culture. Cryptococcus neoformans grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44238=[""].join("\n");
var outline_f43_12_44238=null;
var title_f43_12_44239="Schematic CVVHDF pre-filter";
var content_f43_12_44239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Schematic of CVVHDF with pre-filter infusion of replacement fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 279px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_12_44239=[""].join("\n");
var outline_f43_12_44239=null;
